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5ABSTRACT
Type 2 diabetes is a serious cause of morbidity and mortality and the disease is reaching
epidemic proportions in the developed world. A core defect in type 2 diabetes is insulin
resistance in skeletal muscle. Previous global gene expression experiments conducted at the
Garvan Medical Research Institute has shown that 3 weeks high fat feeding induced increased
expression of stress related genes in rat muscle. These stress-related genes could be involved in
the development of insulin resistance in rat muscle in vivo. However, it is not known whether the
observed effect on stress associated gene expression in rat muscle is a direct effect of increased
fatty acid availability or if the change in gene expression in rat muscle are a secondary effect of
increased dietary fat intake.
To investigate the direct action of free fatty acids on gene expression we examined the effect of
24 and 48 h exposure to 1mM linoleate on gene expression on a cultured muscle cell line
(cultured L6 myotubes).
RT-PCR results showed that linoleate did not upregulate any of the stress-genes measured in L6
rat muscle cells neither after 24 nor 48 hours. This indicates that either free fatty acids have a
secondary effect on upregulation of stress-associated genes in rat muscle in vivo or that L6
myotubes may not be an appropriate model for comparison with in viv effec s.
To further investigate the impact on gene expression on muscle imposed by exposure to free
fatty acids, an AffymetrixÔ  global gene expression analysis was conducted on mRNA from 24
hour linoleate treated L6 rat muscle cells and appropriate control cells. This experiment
confirmed the previous RT-PCR measurements, but also revealed that there is a substantial
difference in gene expression between cultured L6 rat muscle cells and red gastroc rat muscle in
vivo.
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1. INTRODUCTION
1.0 Insulin
Insulin is the key anabolic hormone involved in the storage and controlled release of energy in
the body. Deficiency in its secretion and action is central in all types of diabetes.
Insulin is a pancreatic polypeptide hormone consisting of one 21 and one 30-aminoacid chain
joined by disulphide bonds. Increased blood concentrations of glucose, arginine and glucagon
lead to increased insulin production and release from the b -cells of the pancreatic islets of
Langerhans. This leads to a wide array of effects including increased glucose uptake in skeletal
muscle and adipose tissue, increased glycogen synthesis in liver and muscle and increased
triglyceride storage in adipose tissue. Insulin also affects protein synthesis.
1.1 Type 2 diabetes
Type 2 diabetes (also known as Non-Insulin Dependent Diabetes Mellitus; NIDDM) affects over
150 million adults worldwide and the incidence of this condition is expected to double over the
next 25 years (1). The prevalence of diabetes in adults worldwide was estimated to be 4.0% in
1995, and with this figure expected to rise to 5.4% the year 2025 (2) there is no doubt as to the
epidemic nature of diabetes (3).
Type 2 diabetes normally affects older adults, although it has been reported that type 2 diabetes
is becoming more common among children and young adults in some developed countries (4).
The underlying causes of type-2 have not been fully elucidated; however, type 2 diabetes is
clearly a heterogeneous disorder with genetic and acquired components (5). The environmental
factor is supported by the fact that the geographical distribution of the disease is highly shifted
towards the developed world. The presence of a proven correlation between obesity and type 2
diabetes also supports the environmental component in the development of the disease (6). It is
only recently that obesity has become a medical problem for the developed countries. It is also
interesting that some ethnic groups, such as the Pima Indians are far more disposed to type 2
diabetes than most people, which clearly imply that there is a genetic component in the
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development of the disease (7). Type-2 diabetes is a serious cause of mortality and morbidity and
is strongly related to complications such as risk of cardiovascular disease, retinopathy,
neuropathy and nephropathy.
1.2 A simplified model of insulin signalling in skeletal muscle
The insulin receptor is a tyrosine kinase that undergoes autophosphorylation upon insuln
binding. When phosphorylated, the receptor catalyses the phosphorylation of several proteins
resulting in a wide array of effects. The insulin receptor substrate (IRS) family is among these
phosphorylated proteins. IRS binds and activates phosphatidylinositol-3-OH kinase (PI(3)K)
which catalyses phosphorylation of phosphatidylinositol (PI) in the membrane generating PI
3,4,5 triphosphate, which in turn activates phosphoinositide-dependent kinase-1 (PDK-1).
IRS1
  PI(3)K
PKB  aPKC
GSK3 GLYCOGEN
SYNTHESIS
GLUT4
TRANSLOCATION
EXTRACELLULAR
SPACE
CYTOSOL
GLUT4
INSULIN
RECEPTOR
 PDK-1
Figure 1.2.1 A schematic overview of glucose related insulin signaling. PI(3)K, phosphatidylinositol-3-OH kinase;
IRS1, insulin receptor substrate-1; PKB, protein kinase B; aPKC atypical protein kinase C; GLUT4, glucose
transporter 4,; GSK3, glycogen syntase kinase 3; GS, glycogen synthase
.
GLUCOSE
GS
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PDK-1 activates protein kinase B (PKB), also known as v-akt and atypical protein kinase C
(aPKC) ultimately leading to several effects. These effects includes increased glucose influx as a
result of translocation of glucose transport protein 4 (GLUT4) containing vesicles to the cell
membrane, as well as stimulation of glycogen synthesis (8).
1.3 The pathogenesis of type 2 diabetes
Type 2 diabetes is characterised by excessive hepatic glucose production, decreased or
inappropriate insulin secretion as a result of progressive b -cell dysfunction, and insulin
resistance (9).
The first measurable sign of type 2 diabetes development is insulin resistance. Insulin resistance,
or the failure of target tissue to respond appropriately to physiological concentrations of insulin,
can appear in tissues such as liver and muscle 10-20 years before the onset of type 2 diabetes,
although not everyone with insulin resistance develops type 2 diabetes. During the early stages
of insulin resistance the decreased tissue response to insulin is compensated for by increased
insulin secretion by b -cells in the pancreas (10). After some time, the insulin resistance becomes
so severe that it can not longer be compensated for by increased insulin secretion, and glucose
intolerance occurs (11, 12).
Impaired b -cell function is often the long-term consequence of the hyperinsulinaemic/insulin
resistant state, leading to elevated blood glucose concentration and development of type 2
diabetes. Although there is evidence for a genetic predisposition to b -cell fa lure, there are also
other parameters that influence b -cell function. Amongst these is the prolonged elevation in free
fatty acid blood concentration, which is thought to impair b -cell function by specifically
desensitising the b -cell response to glucose (13).
There are several physiological parameters that change as type 2 diabetes develops. An increased
glucose production and approximately 60% down regulation in glycogen formation by the liver
is seen in type 2 diabetics owing to inadequate suppression of glucose synthesis and inhibition of
glycogen synthesis by insulin. This, together with impaired glucose uptake and glucose
catabolism in the peripheral tissues leads to an elevated blood glucose concentration and an
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impaired glucose tolerance (10, 14). Muscle accounts for up to 75 % of insulin-stimulated
glucose whole body uptake via regulation of GLUT 4 transporter, whereas adipose tissue
accounts for only a small fraction. This implies that insulin resistance in muscle plays a central
role in the development of hyperglycaemia in type 2 diabetics.
Insulin resistance in adipocytes leads to increased lipolysis, which results in an elevated
circulating free fatty acid concentration. A high free fatty acid concentration stimulates the
production of very low-density lipoprotein (VLDL) in the liver, and its release into the
circulation. Dyslipidaemia can result in vascular complications and also increases the insulin
resistance by reducing glucose muscle clearance and increasing glucose output from the liver
(15).
1.4 Possible mechanisms in the development of insulin resistance
There are several factors in addition to the genetic predisposition that can cause insulin
resistance; such as obesity, pregnancy and a hormone excess (16). There is a strong link between
excessive body fat, especially central abdominal fat, and insulin insensitivity (17).
In 1963, Randle et. al.proposed a mechanism known as the Randle cycle, which implied that
increased fatty acid oxidation caused the inactivation of mitochondrial pyruvate dehydrogenase,
ultimately leading to decreased glucose uptake (18).
Since then there have been several other proposed underlying mechanisms for the fatty acid
induced development of insulin resistance, and several of these mechanisms are overlapping. In
the following some of these mechanisms are outlined:
1.4.1 LCACoA
The first step in the metabolism of free fatty acids after they have entered the muscle cell, is the
covalent attachment of coenzyme A (CoA) by acyl-CoA synthase (ACS), forming long-chain
acyl CoA (LCACoA) (19). The activated fatty acids have several fates; including b -oxidation in
the mitochondria and conversion to intramuscular triglyceride initiated by glycerol-3-phosphate
acyl transferase (GPAT). There is evidence that accumulated intramuscular fat, in the form of
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activated LCACoA or stored triglycerides, is linked with insulin resistance in animals and
humans (20, 21).
This muscle cell lipid accumulation can be caused by an increased uptake of systemic available
fatty acids, but the most probable reason is a reduced import into the mitochondria and a reduced
b  -oxidation, leading to an increased cytosolic LCACoA concentration (19).
LCACoA has direct effects on muscle cell metabolism through modulation of enzyme activity of
several key enzymes, including inhibition of hexokinase (22), a key enzyme in glucose
metabolism.
Palmitoyl-CoA is a precursor for de novo synthesis of ceramide, a signal molecule known to
influence insulin sensitivity, as described in more detail below, and it has been speculated
whether increased ceramide synthesis through increased substrate availability could have an
indirect effect on insulin signalling.
Glucose
FA FA LCACoA
Tri glycerides
Glucose 6P
HK
CERAMIDE
PKC
DAG
Insulin receptor
Active FA
transport
Figure 1.4.2 Effects of elevated intracellular long chain acyl coA (LCACoA). HK, hexokinase;
DAG, diacyl glycerol; PKC, protein kinase C; FA, fatty acid
Introduction
12
There is also evidence that LCACoAs can activate specific subtypes of protein kinase C (PKC)
either directly or by acting as a percursor for increased 1,2-diacylglycerol (DAG) (as described
in more detail below).
1.4.2 PKC
The Protein Kinase C (PKC) family consists of several isoenzymes divided into classical, novel
and atypical subclasses. The PKCs translocate to the membrane upon activation and
phosphorylate serine threonine residues on target proteins, including the insulin receptor and
insulin receptor substrate-1 (IRS-1). Activation of certain PKCs, such as the novel PKCe and
PKCq  by increased lipid availability in muscle, is strongly associated with insulin resistance
(23).
Experiments have shown a decrease in the phosphorylation of tyrosine in the insulin receptor
(IR) and the IR substrate (IRS)-1 in muscle from rats after treatment with free fatty acids. Pre-
treatment with a PKC inhibitor prevented this effect, suggesting that PKC has a central role in
fatty acid influence on insulin signalling (24).
Recently, it has been shown that not only activation of classical and novel but also atypical PKCs
(aPKCs), involved in GLUT4 translocation, are important in the regulation of insulin sensitivity.
In 2003, Beeson et al. (25) demonstrated a decrease (70-80%) in insulin stimulated aPKC
activation in subjects with impaired glucose tolerance and in type 2 diabetics compared to
control subjects. This implies that aPKC activation and skeletal muscle insulin sensitivity are
linked. Another study (26) supports this, showing an insulin stimulated decrease in activation of
the aPKC isoforms PKCl /z  in obese and diabetic subjects compared to PKCl /z activation in
lean subjects.
1,2-diacylglycerol (DAG), an intermediate in triglyceride and phospholipid metabolism, has
been found to accumulate in insulin resistant muscle. DAG is a widespread intracellular second
messenger and it has been suggested that there is a link between accumulation of DAG in muscle
and decreasing insulin sensitivity through DAG activation of PKC (27)
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1.4.3 Ceramide
Ceramide is known to be involved in intracellular signalling (28) and it has been suggested that
intracellular ceramide concentration is linked to insulin sensitivity (29). Ceramide is generated
by sphingomyelinase from sphingomyelin, a widely distributed cell membrane component, or
synthesised de novo from serine and palmitoyl-CoA (30).
Interestingly, there is evidence that TNFa  is an activator of sphingomyelinase, and that ceramide
may be a second messenger in TNFa  signalling (figure 1.4.3) (23).
Ceramide appears to be act via phosphatase 2A(PP2A). PP2A is reported to inhibit the synthesis
of glycogen through inhibiting regulatory phosphorylation by protein phosphatase-1 (PP1). In
addition, dephosphorylation, and hence deactivation of PKB mediated by PP2A, can lead to
impaired insulin sensitivity. Incubation of adipocytes with ceramide has shown a 50% decrease
in the insulin-stimulated glucose transport by inhibiting GLUT4 translocation and activation of
PKB(31).
Finally, some isoforms of PKC including PKCz , have been reported to be directly activated by
ceramide leading to interference with insulin signalling (32).
Serine Palmitoyl-CoA
   Dihydroceramide Ceramide
Sphingomyelin
Spingomyelinase   TNF
Figure 1.4.3 Intracellular ceramide synthesis and activation of sphingomyelinase by
tumour necrosis factor-a  (TNF-a ). Figure adapted from (23).
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1.4.4 Hexosamine pathway
The hexoamine pathway is the conversion of fructose-6-phosphate into UDP-N-acetyl-
glucosamine initiated by the rate limiting enzyme glutamine:fructose-6-phosphate
amidotransferase (GFAT). The hexosamine pathway is thought to be involved in nutrient
sensing, and an increased flux through the pathway, initiated by for example increased fatty acid
availability, is associated with decreased insulin sensitivity (33, 34).
The underlying mechanisms for the effect of hexosamines are not fully understood. One
possibility is that increased production of protein glycosylation substrate by the hexosamine
pathway affects the specific O-glycosylation of proteins (34). Several proteins are O-
glycosylated, including IRS-1 (35) and glycogen synthase (36) and although the precise
functional consequences of O-glycosylation are unclear it seems reasonably to assume it has
some functional significance.
It has been demonstrated that glucosamine exposure increased the activity of PKC in rat
adipocytes, which could also be an explanation for the hexosamine-pathway-effect on insulin
GLUCOSE
    G-6-P
   F-6-P Glucosamine-6-P
 GFAT
Acetyl-CoA UDP-Acetyl-G
Figure 1.4.5 Overview of the hexosamine pathway. G-6-P, glucose-6-phosphate; F-6-
P, Fructose-6-phosphate; GFAT, glutamine:fructose-6-phosphate amidotransferase;
UDP-acetyl-G. UDP-acetyl-gucosamine.
Targets for
insulin signaling
Insulin receptor
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signalling in muscle. In addition in vitro studies has also demonstrated that a PKC inhibitor
reversed, glycosamine induced insulin resistance in adipocytes (37).
Hexosamines are also known to stimulate transforming growth factor-b  (TGFb ) transcription and
and hence production of extracellular matrix which, in turn can inhibit insulin signalling (38).
This could be an alternative explanation on the hexosamine effect on insulin sensitivity in
muscle.
1.4.5 TNF
Tumour necrosis factor-a  (TNFa ) together with, adiponectin, resistin and others, forms a class
of biologically active message molecules known as adipokines. While adiponectin and leptin, a
hormone secreted from the adipocytes are associated with increased insulin sensitivity (39, 40),
TNFa  and resistin are associated with the development of insulin resistance (41, 42). TNFa  is
secreted from several cell-types including adipocytes and is found to be overexpressed in obese
humans (43). Since TNFa  stimulates lipolysis and inhibits lipogenesis in adipose tissue it is
thought be an important mediator of insulin sensitivity, although knockout experiments of the
TNFa  gene provided only partial protection against obesity-induced insulin resistance (44).
Insulin-stimulated glucose uptake and activation of glycogen synthase is reported to be decreased
by TNFa  in rat skeletal muscle in vitro (45), although others have reported that TNFa  does not
seem to have any effect on the ability of insulin to increase glycogen synthesis in cultured human
muscle cells (46).
TNFa  acts on the TNFa -receptor and initiates several signalling pathways (figure 1.4.1)
including activation of the dimeric transcription factor Nuclear Factor-k B (NFk B) (41, 47). In its
inactive form, NFk B is located in the cytoplasm bound to the inhibitor protein Ik B. When the
TNFa  receptor is stimulated, a serine kinase cascade leads to phosphorylation of Ik B by Ik B
Kinase (IKK), which leads to its protosome mediated degradation. This releases NFk B and it is
translocated from the cytoplasm to the nucleus where it binds to DNA, initiating transcription of
several genes including pro-inflammatory and pre-adipocyte genes. NFk B also r gulates the
expression of TNFa . IKK is built up of two subunits, IKK-a  and IKK-b . Interestingly, the
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b -subunit has been identified as the cellular kinase responsible for TNFa  induced IRS-1
phosphorylation. (48).
A more indirect way in which TNFa  can influence insulin sensitivity is by repression of
adiponectin gene expression. Adiponectin is reported to have an enhancing effect on insulin
sensitivity (40), and while insulin stimulates adiponectin secretion in vitro, TNFa  potently
represses adiponectin mRNA levels in adipocytes (49). Recently, two adiponectin receptors,
adiponectin receptor 1 (AdipoR1) abundantly expressed in muscle and adiponectin receptor 2
(AdipoR2) present in the liver were cloned by Yamauchi et. al.(50). These receptors could be
novel drug targets in the treatment of type 2 diabetes.
Several factors, other than TNFa  can lead to activation and translocation of NF-k B, including
p38 MAPK, oxidative stress and IL-1b  exposure.
Figure 1.4.1 Intracellular TNFa
receptor signaling and NFk B
activation. TNF, tumour necrosis
factor; IKK, Ik B kinase; JNK, c-Jun
amino-terminal kinase.
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1.5 Oxidative stress and insulin resistance
There is an increasing body of evidence linking insulin resistance and stress-activated signalling
pathways. Some of the findings implying that oxidative stress-sensitive gene expression and
insulin sensitivity are related include:
·  It has been reported in both animal models and in muscle cells in vitro that in ulin resistance
induced by either hyperglycaemia or by increased free fatty acids can be prevented by
administration of antioxidants such as a -lipoic acid (LA), N-acetylcysteine and vitamin E
(51),(52),(53). The acute and long-term protective effect of LA has also been demonstrated in
humans with type 2 diabetes (54).
·  It has recently been discovered that some genes involved in providing cellular protection
against oxidative stress, are down regulated in skeletal muscle in people with type-2 diabetes
(including heat shock protein 72 and oxygenase-1)(55).
·  A major intracellular target of oxidative stress is the transcription factor NFk B. IKK b , a
kinase which regulates the NFk B pathway has been found to be increased in insulin resistant
muscle (56). Salicylates which are known to inhibit IKKb  activity have been shown to protect
against fat-induced insulin resistance and lower blood glucose in rats (57).
·  The c-Jun amino-terminal kinase (JNK), a protein in the stress sensitive JNK/SAPK pathway
has been shown to be substantially upregulated in obese and insulin resistant mice, whereas mice
JNK1(-/-), but not JNK2(-/-) knock out mice had decreased weight and significantly improved
insulin resistance. This suggests that the JNK/SAPK pathway plays a role in the pathogenesis of
type 2 diabetes.
Mitochondria are the main site for the generation of free radicals. In the process of respiration a
fraction of the oxygen used is converted into reactive oxygen species (ROS) (see figure 1.5.1).
ROS are toxic to the cell but are normally quickly detoxified by several defence mechanisms,
including, catalase, superoxide dismutase (SOD) and glutathione (GSH) peroxidase/reductase
(Figure 1.5.1). Both increased free fatty acid concentrations and hyperglycaemia can increase
ROS concentrations (47).
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1.6 Lipid metabolism in skeletal muscle
As discussed in the previous section, it is well established that fatty acids influence insulin
sensitivity in skeletal muscle although the exact mechanism behind this is not known. The
impact of fatty acids may be direct or indirect through a lipid metabolite (such as  diacyl glycerol
(DAG)). In this section fatty acid metabolism in skeletal muscle is briefly reviewed.
1.6.1 Transport of fatty acids into muscle cells:
Fatty acids (FA) are highly hydrophobic, do not dissolve freely in blood and are bound to
transport proteins (albumin and lipoproteins) while circulating in the bloodstream. When FAs are
Free fatty acids
Hyperglycemia
 .
OH
O2
- H2O2
SOD
H2O
 Catalase
    GSH
Cu, Fe
STRESS SENSITIVE
PATHWAYS
Figure 1.5.1 Overview of reactive oxygen species generation, degradation, influence on gene
transcription and dephosphorylation of IRS-1(insulin-receptor-substrate-1). SOD, superoxide
dismutase; GSH, glutathion; IKK, Ik B Kinase; NFKB, Nuclear-factor-KB; JNK, c-Jun amino-
terminal kinase 
peroxidase/reductase
IRS-1 IRS-1IKK
NFk B
    JNK? ?
STRESS SENSITIVE TRANSCRIPTION
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transported from adipose tissue they are transported as non-esterified fatty acids (NEFA) bound
to albumin, an abundant blood protein. Other protein-containing structures that transport FAs
include lipoproteins such as chylomicrons which transport dietary fat taken up by the gut, and
very low-density lipoproteins (VLDL) which are secreted from the liver. Both in chylomicrons
and VLDLs fatty acids are transported esterified to glycerol (triacylglycerol). On reaching the
muscle cell, triacylglycerol is hydrolysed into fatty acids by lipoprotein lipase, after which it
enters the cell via simple diffusion or active transport. There is evidence of passive transport of
FAs across the cell membrane through a “flip-flop” mechanism (58), and there is no doubt that
this mechanism can contribute to the FA translocation, although views vary on the contributing
effect of this compared to active transport.(58, 59)
There are several suggested mechanisms for active FA transport across the cell membrane. One
paper (60) suggests that long-chain FAs (LCFA) are actively transported either directly through
fatty acid transport proteins (FATPs) or by first attaching to fatty acid transporter (FAT/CD36),
which then hands over the FFA to the FATPs (as illustrated in figure1.6.1).
Figure 1.6.1 Proposed mechanism
for active fatty acid translocation.
LCFA, long-chain fatty acid; FABP,
fatty acid binding protein; ACBP,
acyl CoA binding protein; LCACS,
long-chain fatty acyl-CoA
synthetase; FATP, fatty acid
transport protein.
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It has been reported that overexpression of FAT/CD36 in mice skeletal muscle leads to enhanced
fatty acid oxidation and reduced circulating triglycerides and fatty acids (61), while FAT/CD36
deficiency in mice increases insulin sensitivity in muscle and decreases insulin sensitivity in
liver(62). It has also been reported that insulin can stimulate uptake of FAs through cellular
redistribution of FAT/CD36 (63). Together, these findings imply that FAT/CD36 has a central
role in the translocation of FAs into the cytosol in muscle. Peroxisomal proliferator-activated
receptors (PPARs), which can be activated by fatty acids, seem to regulate the expression of
FAT/CD36 and FATPs.
Once inside the cell, the FAs are esterified by long-chain fatty acyl-CoA synthetase (LACS) or
fatty acyl-CoA synthetase (ACS) to coenzyme A (CoA), which activates the FAs for
mitochondrial transport and oxidation. The esterified FA are also more hydrophilic than FAs,
which prevents passive leak of FAs into the extracellular space. Fatty acid binding proteins
(FABP)s and acyl CoA binding protein (ACBP) respectively bind FAs and the esterified
LCACoAs, increasing their cytosolic solubility.
1.6.2 Fatty acid storage in muscle cells
The main site for fatty acid storage is as triglyceride in adipose tissue. Lipids can also be stored
in muscle, although only to a limited extent compared to adipose tissue. Intramuscular
accumulation of triglycerides has been found to correlate with decreased muscle insulin
sensitivity (64, 65). The first step of triglyceride synthesis de novo is the esterification of
LCACoA to glycerol-3-phosphate, catalysed by glycerol 3-phosphate acyl transferase (GPAT).
Insulin influences the rate of triglyceride synthesis by regulating GPAT activity (66).
There is some evidence that reduced fatty acid oxidation rather than increased uptake is more
important in elevating lipid (LCACoA) concentration in muscle (67, 68) and since de novo fatty
acid synthesis is minimal in skeletal muscle (69) the rate of oxidation would also influence the
rate of intramuscular triglyceride synthesis. Polyunsaturated fatty acids (PUFAs) have been
shown to reduce triglyceride accumulation in skeletal muscle (70). Thi  suggests that not only
the concentration of intramuscular FA (LCACoA) but also the type of fatty acid influences the
amount of intracellular triglyceride synthesised.
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1.6.3 Fatty acid oxidation in muscle cells
Fatty acid oxidation in the muscle is predominantly located to the mitochondria, but fatty acid
oxidation also occurs in peroxisomes (71). Before the LCACoA can be oxidised in the
mitochondrion, it has to be transported across the mitochondrial membrane. Carnitine palmitoyl
transferase (CPT) 1, which is located on the outside of the mitochondrial membrane, is  thought
to be the rate-limiting enzyme in this process. CPT1 converts LCACoA to acyl-carnitine (AC).
AC is transported across the membrane and converted back to LCACoA by CPT2. Malonyl-
CoA, an early intermediate in fatty acid synthesis, is an inhibitor of CPT1, and elevated
TCAAcetyl-CoA
GLUCOSE
Citrate
CPT1
LCACoA
 LCACoA
-oxidation Acetyl-CoA
Malonyl-CoA
ACC
FAS
 CL
TG
 GPAT
   ACS
FA          FA
Glucose-6P
HK
Pyruvate
PDH
+
Figure 1.6.2 Overview of fatty metabolism. CPT1, carnitine palmitoyl transferase; ACC, acetyl CoA carboxylase, CL,
citrate lyase; FAS, fatty acid synthase; GPAT, glycerol 3-phosphate acyl transferase; PDH pyruvate dehydrogenase
complex; HK, hexokinase.
Introduction
22
concentrations of malonyl-CoA can lead to cytosolic accumulation of LCACoAs which can by
mechanisms previously described lead to insulin resistance (69).
Once inside the mitochondrion the LCACoA is fully oxidised by b -oxidation to water, CO2 and
energy.
1.6.4 Transcriptional regulation of fatty acid metabolism by PPARs
The peroxisome proliferator-activated receptors (PPARs) are a family of ligand-activated
transcription factors that are activated by several agonists including some lipids, for example
polyunsaturated fatty acids (PUFAs). There are several isoforms of PPARs; PPARa , highly
expressed in many tissues including liver, muscle, and heart; PPARd , which is ubiquitously
expressed and PPARg  highly expressed in adipose tissue. All three PPAR subtypes bind to DNA,
as hetrodimers with retinoid X receptor (RXR) subtypes upon agonist activation (72) and
regulate the expression of genes involved in lipid metabolism (73). Some of these genes include
FATP, CD36/FAT (74), acyl-CoA synthase (75) and CPT1 (76). PPAR activity has been more
thoroughly studied in adipose tissue and liver than in skeletal muscle but, studies show that the
expression of PPAR-responsive genes are enhanced when cultured skeletal muscle cells are
incubated with fatty acids or specific synthetic ligands for PPAR isoforms. This demonstrates
that PPARs may also have a regulating role in muscle energy metabolism (77). Both PPARa  and
PPARg  are abundantly expressed in skeletal muscle and it has been demonstrated that PPARa
plays a role in regulating lipid homeostasis in human muscle cells.
PPARd  is also expressed in muscle cells and has been shown to be at least partially responsible
for the dual effect of long chain fatty acids, both as inhibitors of myogenesis and inducers of
transdifferentiation into preadipose-like cells. This is for example seen in cultured C2C12 mouse
muscle cells (78). Recent in vitro studies suggests that PPARd  plays a central role in the
regulation of fatty acid oxidation in skeletal muscle. It has been demonstrated that fatty acid
treatment or treatment with synthetic PPARd  -agonist induces genes involved in lipid
metabolism in C2C12 mouse muscle cells (79, 80).
Introduction
23
1.7 Aims
Previous microarray data from research at the Garvan Institute of Medical Research has
revealed that mRNA expression of genes that are involved in stress pathways are upregulated
in insulin resistant skeletal (red gastroc) muscle from high-fat fed rats compared to normal
(chow fed) rats. It is not known whether the dietary fatty acids have a direct effect on stress
pathways in muscle cells or if the changes in the stress-associated gene expression observed
are due to an indirect effect of the high fat diet.
The purpose of the study is firstly to see whether exposure of cultured L6 rat muscle cells to
1mM fatty acid (linoleate) gives a similar change in stress associated gene expression as seen
in high-fat-fed rat muscle in vivo. The modulating effect of the cytokine TNFa  and the PPARg
agonist rosiglitazone on stress associated gene expression in L6 cells is also investigated.
A second goal is to examine the degree of similarity in gene expression between a cultured
differentiated rat muscle cell line and red gastroc rat muscle in vivo.
Finally, this study aims at evaluating whether cultured L6 rat muscle cells would be a suitable
in vitro model for further research on the mechanisms behind modulation of stress sensitive
gene expression in muscle from high-fat-fed rats.
2.1 ABBREVIATIONS
ACBP - acyl CoA binding protein
ACC - acetyl CoA carboxylase
ACS - acyl-CoA synthase
ADD1- adipocyte determination- and differentiation-dependent factor 1
AdipoR1 - adiponectin receptor 1
AdipoR2 - adiponectin receptor 2
aPKC – atypical protein kinase C
BSA - bovine serum albumin
BTEB - basic transcription element binding protein
CL - citrate lyase
CL-6 - growth responce protein
CoA - coenzyme A
COX-2 - prostaglandine-endoperoxide synthase 2
CPT1 - carnitine palmitoyl transferase
DAG - 1,2-diacylglycerol
DMSO – dimethyl sulfoxide
DNA b.p. - DNA binding protein
dNTP – deoxyribonucleotide triphosphate
ERK – early responce kinase
EST - expressed Sequence Tags
FA - fatty acid
FABP - fatty acid binding protein
FAT/CD36 - fatty acid transporter
FATP - fatty acid transport protein
FCS- fetal chalf serum
GAPDH – glyceraldehyde-3-phosphate-dehydrogenase
Gastroc - gastrocnemius
GLUT1 - glucose transporter 1
GLUT4 - glucose transport protein 4
GMA - Growth Medium A
GMB - Growth Medium B
GO - Gene Ontology
GPAT - glycerol-3-phosphate acyl transferase
GS - glycogen synthase
GSH - glutathione
GSK3 - glycogen syntase kinase 3
HK - hexokinase
HMG-hydroxy-methylglutaryl
IKK - I k B Kinase
IR - insulin receptor
IRS - insulin receptor substrate
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IVT - in vitro transcription
JAK2 - Janus kinase 2
JNK - c-Jun amino-terminal kinase
LA - a -lipoic acid
LCACoA - long-chain acyl CoA
LCACS - long-chain fatty acyl-CoA synthetase
LDL – low density lipoprotein
MAPK - mitogen activated protein kinase
MAS - The Micro Array SuiteÔ
MEM- minimal Essential Medium
mRNA – messenger ribonucleic acid
NEFA - non-esterified fatty acids
NFk B - nuclear Factor-k B
NGFI-B – nerve growth factor I-B
NIDDM - Non-Insulin Dependent Diabetes Mellitus
PBS – phosphate buffer
PCR - polymerase chain reaction
PDH - pyruvate dehydrogenase complex
PDK-1 - phosphoinositide-dependent kinase-1
PI(3)K - phosphatidylinositol-3-OH kinase
PKB - protein kinase B
PP1 - protein phosphatase-1
PP2A - phosphatase 2A
PPARs - peroxisomal proliferator-activated receptors
PUFAs - Polyunsaturated fatty acids
ROS - reactive oxygen species
RT - reverse transcriptase
RXR - retinoid X receptor
SAPE - streptavidin phycoerythrin
SOD - superoxide dismutase
SREBP-1 - sterol regulatory element-binding transcription factor 1
TGFb  - transforming growth factor-b
TNF-a  - tumour necrosis factor-a
UCP3 - uncoupling Protein-3
VLDL - very low-density lipoprotein
2.2 MATERIALS AND METHOD:
2.2.1 L6 cell growing, splitting and differentiation
Establishing tissue culture of L6 myoblasts
In sterile conditions, an ampoule of L6 myoblasts cells was thawed rapidly at 37 ° C. The cells
were carefully resuspended in a 150cm2 flask containing Growth Medium A (GMA) (MEM/10%
FCS/10% Antibiotic/antimyotic) equilabratid to 37 ° C. The cells were incubated at 37° C  in a
5% CO2 atmosphere. The medium was carefully decanted and replaced with another 20ml GMA
after 2 hours of incubation to remove DMSO originating from the L6 freezing medium. The cells
were then further incubated until they were 60-80% confluent. The flasks were inspected daily
under a microscope.
Splitting of cells
At 60-80% confluence, usually every 3-4 days, the cells were split to avoid cell differentiation
and maintain passages. After removing the growth medium by vacuum, the cells where washed
twice using 2x20ml PBS (0.36% Disodium Hydrogen Ortophosphate, 0.02% Potassium
Chloride, 0.024% Potassium Dihydrogen Phosphate, 0.8% Sodium Chloride). The cells were
detached from the flask by adding 5mL trypsin (Gibco) for about 10 seconds. The trypsin was
carefully decanted and replaced with 10ml Growth Medium B (GMB) (MEM/2% FCS (Gibco)/
10%Antibiotic/antimyotic (Gibco)). The cells came into suspension by gently tapping the side-
walls of the flask. The cell suspension was then decanted into a sterile 50ml tube and 20ml GMA
was added. The serum in the medium deactivates the trypsin. 0.3ml of the cell suspension was
added to a new 150 cm2 flask containing 20ml GMA and incubated at 37° C  in a 5% CO2
atmosphere until the cells had grown to 60-80% confluence.
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Seeding of cells on plates
After 2 passages there were enough cells to seed them into 10cm plates.
The growth medium was removed by vacuum and the cells were washed twice with 20ml PBS.
5ml trypsin was added to detach the cells. The trypsin was carefully removed and replaced with
10ml GMA. The cell suspension was then decanted to a sterile 50ml tube and the cell
concentration was determined using a haemocytometer. 10ml GMA was added to each plate
(10cm). The cell suspension volume containing 4x105 cells was calculated and added to the
plates. The plates were gently swirled and then incubated at 37° C  in a 5% CO2 atmosphere for
48 hours.
Differentiation of cells
The L6 muscle cells differentiate into myotubes when treated with a low serum content medium.
The GMA medium was removed from the plates by vacuum and replaced with 7.5ml GMB and
incubated at 37° C in a 5% CO2 atmosphere for 10 days. The GMB was replaced every 24 hours
and the plates were inspected under a microscope daily.
2.2.2 Preparation of treatment solutions
Linoleate solution
1.87g BSA (Bovine Serum Albumin, Fatty acid free, SIGMA) was dissolved in 9.37ml medium
(2% FCS MEM) on a roller for 30 min at room temperature to make a 20% BSA solution. A
28mg/ml solution of linoleate (18:2 (n-6)) in ethanol was made from freshly thawed pure
linoleate. The linoleate stock was stored at –80° C under an argon atmosphere to avoid oxidation.
375µl 28mg/ml linoleate solution was added into the freshly made 20% BSA solution in sterile
conditions. The BSA solution was pre-heated to approximately 37° C to avoid linoleate from
coming out of solution. The combined linoleate and BSA solution was then filtered (0,22µm)
into 28,1ml sterile 2% FCS MEM to give a final linoleate concentration of 1mM in 5% BSA 2%
FCS MEM.
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Rosiglitazone control solution
10mg of Rosiglitazone (Rosiglitazone-maleate, GlaxoSmithCline) was dissolved in 211 µl
DMSO and 20µl of this solution was added into 20 ml 2% FCS MEM. 20ml of the combined
solutions were filtered (0.22µm) into 20ml media (2% FCS MEM) under sterile conditions.
Finally 16µl of this solution was added into 8ml 5% BSA 2% FCS MEM under sterile conditions
to give a final Rosiglitazone concentration of 2x10-7M.
Rosiglitazone linoleate solution
10mg of Rosiglitazone was desolved in DMSO and in into 20 ml 2% FCS MEM as described
above. 16µl of this solution was added into 1mM linoleate 5% BSA 2% FCS MEM prepared as
described above, to give a final Rosiglitazone concentration of 2*10-7M a d a final linoleate
concentration of 1mM.
 TNF  solution
4ml of TNFa  stock solution (10µg/ml, Recombinant Human, R&D System ) was added into 8ml
2% FCS MEM to give a final TNFa  concentration of 5ng/ml. The solution was filtered (0.22µm)
in sterile conditions.
2.2.3 L6 rat muscle cell treatment
Growth medium was removed from the differentiated L6 muscle cells by vacuum and replaced
by the treatment medium. Each treatment solution was added to two separate plates with
differentiated L6 rat muscle cells (Figure 2.2.3.1). One was incubated at 37° C in  5% CO2
atmosphere for 24 hours and the other was incubated at the same conditions for 48 hours.
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CONTROL: LINOLEATE:
8ML 8ML 
2% FCS MEM 1mM LINOLEATE
5% BSA 2% FCS MEM
5% BSA
ROSIGLITAZONE- ROSIGLITAZONE 
CONTROL AND LINOLEATE
8ML 8ML 
2*10-7M Rosiglitazone 2*10-7M Rosiglitazone
2% FCS MEM 1mM LINOLEATE
5% BSA 2% FCS MEM
5% BSA
TNFalpha- TNFalpha
CONTROL 8ML
8ML 5ng/ml TNFalpha
2% FCS MEM 2% FCS MEM
Figure 2.2.3.1 L6 cell treatment overview. FCS, Fetal Calf Serum;BSA,Bovine Serum Albumin ;MEM, a -Minimal
Essential Medium
2.2.4 Total RNA Isolation and quantification
Total RNA was isolated from the treated L6 rat muscle cells by using Tri ReagentÒ  (Sigma).
The medium was removed from the plates and the cells were washed twice with 10ml PBS.
1.5ml of Tri Reagent was added to the plates in a fume hood and the lysed cells were
immediately harvested using a cell scrape. The lysate was passed through a syringe to make it
homogenous and the RNA was extracted according to manufacturers instructions. The isolated
RNA was stored as a pellet in absolute ethanol at –80° C.
The amount of RNA isolated from the L6 rat muscle cells was measured by fluorometry using a
SYBR Green II assay (81).
The RNA stocks stored at -80° C were washed with 1ml 75% ethanol and the pellets were then
resuspended in 50µl RNase free H2O (AmResco). 5µl of this RNA solution was added to 45µl
RNase free H2O. The stock solutions were stored at -80° C. 2m l and 3m l of the 1:10 RNA
dilutions were added to 1ml freshly made 1:10000 dilution of SYBR green II dye (Molecular
Probes) in 1xTE buffer (10x, 1,2% Tris HCL 10mM, 0.3% EDTA). Standard RNA solutions (50,
100, 200, 400, 600 and 800ng) were made up and 1ml of the same SYBR green II solution was
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also added. The intensity of emitted light was measured using a fluorometer (excitation
wavelength: 468nm; emission wavelength: 525nm), and the RNA concentration of the stock was
measured as the mean value of the two samples calculated from the standards by linear
regression. The 1:10 RNA dilutions were stored at -20° C.
2.2.5 RT-PCR
Reverse Transcriptase
cDNA was made from 1:10 total RNA dilutions stored at -20° C.  A volume of dillution equal to
200ng RNA was added to the master mix (1µl Omniscript, 2m l 10x Buffer, 2µl dNTP, 1m l
oligoprimer (20m M), 0.25µl RNase inhibitor 40u/µl; Quiagen) and RNase free H2O to give a
total volume of 20m l. The mix was incubated for 1 hour in water bath at 37° C. The cDNA made
from the reaction was stored at –20° C.
PCR
PCR primers:
CD36 1 Rat Forward: TTG TTC TTC CAG CCA ACG CC
Reverse: CCA GTT ATG GGT TCC ACA TCC AAG
CD36 2 Rat Forward: GGG`AAA GTT ATT GCG ACA T
Reverse: CAG ATT CAA ACA CAG CAT AGA
cJUN Rat Forward: AGC AAT GGG CAC ATC ACC AC
Reverse: TGG GCA GCG TAT TCT GGC TAT G
DBP Rat Forward: CAA GAA CAA TGA AGC AGC CAA GAG
Reverse: TGA AAG CAC AGC ACG GTA GTG G
NFkB Rat Forward: AAG CAG GAA GAT GTG GTG GAG G
Reverse: GAG TAG GAC CCC GAG GAT TTT ATC
FATP Rat Forward: ATC CGT CTG GTC AAG GTC AAC G
Reverse: AAC ACG CTG TGG GCA ATC TTC
Ikkb Rat Forward: TGG AAG TGA TTG GTC AGG TGA AG
Reverse: GGC AAG ATG GAG AGG GGT ATT TC
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PCR was performed with 1µl RT product, 5µl 10x PCR buffer (Roche), 2µl 25mM MgCl2
(Roche)solution (1mM final concentration), 1µl forward primer, 1µl reverse primer (Proligo®),
0,3µl AmliTaq Gold enzyme (Promega) and RNase free H2O to a final volume of 50µl.
Table 2.2.5.1 Thermocycler parameters for PCR-reaction:
Step Temperature (° C) Number of cycles
1 94 1
2 94 “Cycle number”
2 Annealing temperature “AT”“Cycle number”
2 72 “Cycle number”
3 72 1
Table 2.2.5.2 Primer parameters:
PrimerProduct size AT Cycle number
Cyclophillin 189 53 22
IKK 182 53 26
DNAbinding 160 53 26
          FATP 188 55 37
cJun 136 55 28
NFK 129 55 29
UCP3 154 53 31
PCR products were separated by agarose (LE Analytical Grade, Promega) gel electrophoresis.
Gel concentration was 2% agarose in TAE (4.84% tris acetate, 40mM, 1.15% glacial acetic acid,
2% EDTA 0.5M) buffer and the applied field was 90V for ~1 hour. The cDNA product size was
approximated using a DNA ladder and the DNA bands were detected by UV using ethidium
bromide staining (0.5µg/ml) for 10 minutes followed by a wash in water for 10 minutes. The
relative densities of the visualised PCR products were measured using NIH ImageÒ  software.
2.2.6 LightCycler
Real-time PCR was performed using cDNA from some samples. This was carried out under
standard PCR conditions using 0.6mM of each primer, 3mM MgCl2 and 1m l of purified PCR
product as standard with added water to a final volume of 10m l. The amplification program was
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initially started at 95° C for 10min., then 40 cycles of three steps each, comprised of 95° C for
15s, 55° C for 5s and 72° C for 10s. The fluorescence of the products was measured (494nm
excitation wavelength and 523nm emission wavelength) during each run and for specificity
determination the melting curves for each sample were acquired at the end of each run. The
standard concentrations used was 10-2, 10-4 and 10-5.
2.2.7 Affymetrix GeneChip
Introduction
High density microarray gene expression gives an unique opportunity to simultaneously obtain
gene expression results from thousands of genes and to make comparisons between gene
expression under different conditions.
On an array millions of copies of a single 25 base oligonucleotide probe are grouped as a probe
cell. Each perfect match probe cell has its mismatch match probe cell with an oligonucleotide
sequence similar to the perfect match. There are at least 16 probe pairs for each probe set and
each gene or Expressed Sequence Tags (EST) clusters on the gene chip is represented by at least
one gene set. The U34A genechip contains 8,800 probe sets  and provides gene expression data
for approximately 7,000 full-length sequences and approximately 1,000 (EST) clusters (82).
Perfect match probe cell
Probe      24µm
pair
Mismatch match probe cell
After staining, the intensity of the light emitted from each probe is proportional to the amount of
RNA bound, giving a measure of gene expression. The probe pairs are compared, and probability
Each probe set consists of at least 16 probe pairs
Figure 2.2.7.1  GeneChipÒ , probe set illustration.
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algorithms are used to calculate whether or not an mRNA sequence representing a gene or an
EST is likely to be present, not present or marginally present, and then calculates the abundance
of the mRNA.
Before the mRNA can be hybridised to a gene chip the total RNA has to be purified, labelled,
amplified and fragmented as illustrated below.
RNA from five different 24-hour 1mM linoleate treated L6 rat muscle cells and their controls
were pooled and analysed on two U34A gene chips.
Figure 2.2.7.2 Illustration of the Affymetrix genechip processing.
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Pooling of RNA
The quality of the total RNA from five different 24-hour 1mM linoleate treated L6 cell
experiments and their controls were checked by UV-visualisation on a 1% agarose gel, TBE
(10.8% tris base 89mM, 5.5% boric acid 89mMm, 0.7% EDTA, 2mM), ran at 50V for 1 hour
and developed using ethidium bromide.
The total RNA concentration was determined for all 10 samples using a SYBR green II assay as
previously described. Volume equal to 6m g total RNA was for each of the linoleate treated
samples pooled and RNase free water was added to a total volume of 100m l. The same procedure
was carried out for the five control total RNA samples.
To remove traces of DNA the pooled samples were cleaned on an RNEasy column according to
manufacturers instructions. Total RNA concentration was determined for the pooled and cleaned
samples using the SYBR green II assay previously described.
The pooled RNA samples were diluted to a concentration of 5µg/ml and were prepared for
hybridisation according to the AffymetrixÔ  genechip Expression Analysis technical Manual as
briefly described below.
C1      C2     C3      C4     C5     F1      F2     F3      F4      F5
Figure 2.2.7.3  1% agarose visualisation of control (C) and linoleate (F)
treated L6 muscle cell total  mRNA before pooling.
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Double stranded DNA synthesis:
First strand and second stand cDNA synthesis was performed using T7-(dT)24 primer (Proligo)
and SuperScript Choice system as described in the AffymetrixÔ  protocol.
T7-(dT)24 sequence: GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG-(dT) 24
The double stranded cDNA was cleaned up by phenol:chlorophorm:isoamyl alcohol (saturated
with 10mM Tris-HCl, pH 8.1, 1 mM EDTA) extraction using a PGL-Light tube (Bio-Rad) to
prevent phenol contamination and was then applied and spun through a BioGel column (Bio-
Rad). The cDNA was then precipitated with absolute ethanol and ammonium acetate and the
pellet washed as described in the AffymetrixÔ  pro ocol. The pellet was resuspended in 23µl
RNase free H2O and the cDNA quality ensured by running 3µl of the cDNA solution on a 1%
agarose gel.
                        
A CB
Figure 2.2.7.4  Visualisation of synthesised double stranded DNA (A), IVT
product (B) and fragmented cRNA (C) from the control and linoleate treated
L6 cells.
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In vitro transcription:
In vitro transcription (IVT) was performed by using Enzo Bioarray HighYield Transcript
Labelling Kit according to manufacturers’ procedure. Biotin labelled UTPs and CTPs were
incorporated in to the synthesised RNA made form the cDNA template. The IVT product was
split into two RNEasy columns to optimise the yield and the unincorporated dNTPs was removed
according to manufacturers procedure. 30m l of RNase free H2O was used to elute the RNA. The
total elute volume was reduced to a about 10µl by vacuum centrifuging and the volume was
corrected to 12m l with RNase free H2O. The yield from the IVT reaction was determined by the
SYBR green II RNA quantification assay described above.
Fragmentation
Fragmentation of the cRNA to a base pair length to approximately 35 to 200 pieces of 35 to 200
base pair length was performed on 20m g cRNA by adding 5x fragmentation buffer  (4.0mL 1M
Tris acetate pH 8.1 (Trizma Base, 0.64g MgOAc, 0.98g KOAc, RNase free water to 20mL, pH
adjusted with glacial acetic acid) and incubating at 95° C for 35 minutes. This was carried out in
order to make the cRNA suitable to bind to the 25 base pair oligonucleotides on the gene array.
Gene chip processing
The fragmented target cRNA was diluted with 101m l RNase free H2O and 100x Cocktail Spike,
2x Hybridisation buffer, 1m l control oligotide B2, 3m l Herring Sperm DNA (10mg/ml, Promega)
and 3m l acetylated BSA (50mg/ml, Invitrogen) was added RNase-free H2O to giv a total volume
of 300m l, as described in the AffymetrixÔ  technical protocol. This hybridisation cocktail was
then hybridised to an AffymetrixÔ Test3 gene chip in a hybridisation oven at  45° C, 60rpm for
16 hours to test the quality of the RNA.
After incubation the hybridisation cocktail was removed from the chip and stored at
-80° C for later use. The gene chip was washed and the biotinylated cRNA was stained with
streptavidin phycoerythrin (SAPE) and double stained using normal goat IgG, biotinylated
antibody and SAPE. The procedures were performed using AffymetrixÔ Fluidics Station.
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The control and linoleate Test3 chips were then scanned twice with a Hewlett-Packard
GeneArray Scanner at excitation and emission wavelengths of 488nm and 570nm respectively.
After the results from the Test3 chip confirmed the quality of the RNA the hybridisation cocktail
was applied to a pre-wetted AffymetrixÔ  U34A rat genome gene chip and the hybridisation,
washing/staining and scanning processes described above were performed.
Data analysis:
Test chip results:
Five criteria were met before applying the cRNA hybridisation cocktail to the U34A rat genome
chip:
a) The background noise was less than 150.
b) The applied standards (bioB, bioC, bioD and cre, all genes from E.Coli biotin synthesis
pathway) were present.
c) The probe sets that corresponds to the 3’ and 5’ ends for the mRNA from the housekeeping
genes b -actin and GAPDH did not differ by more than two-fold.
d) The scaled noise, the scale factor and the normalization factor were comparable between the
two test chips.
The above criteria were also met for the U34A gene chip.
Raw data extraction
The expression raw data was calculated from the generated gene chip picture using AffymetrixÔ
Microarray Suite 5. The raw data from the two gene chips were compared using the same
software.
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Affy Analysis Tool
The raw data from the two chips and their comparison were exported to Affy Analysis Tool
v0511 (Dr. Gareth Denyer, The University of Sydney) and were compared to data from
previously performed gene chips on high fat fed rat muscle and liver as described below.
Analysis of the expressed sequence tags (ESTs) is beyond the scope of this project and were
therefore excluded at this stage. The up- or downregulated ESTs are included in appendix II.
MAPPFinder and GenMAP
Further analysis of the microarray results were performed using MAPPFinder and GenMAP
software. MAPPFinder is a tool that creates a global gene-expression profile by integrating the
annotations of the Gene Ontology (GO) project with pathway maps from the GenMAPP software
(83).
Presentation of data:
Results are presented in tables as fold change in the gene expression of the linoleate treated L6
rat muscle cells relative to the control. Since fold change can some times be a misleading
measurement of change, the measured signal intensities are also included to assist in the
interpretation of the result.
Comparison of microarray results to data from previously conducted experiments at the Garvan
Institute of Medical research.
A combined search where conducted on the gene-chip-data from the L6 linoleate-control
comparison and gene-chip-data on muscle and liver from high-fat-fed rat experiments previously
conducted at the Garvan Institute of medical research. The expreiment where conducted with
adult male Wistar rats. The rats where fed chow diet or high-fat diet for 3 1/2weeks prior to the
tissue collection. The combined search where preformed using Affy Analysis Tool v0511.
3. RESULTS
3.0 L6 rat muscle cells
L6 rat muscle cells were used to mimic rat muscle cells in vitro. L6 rat muscle cells were
selected for high fusion (84) and the development of a insulin responsive pool that contained
GLUT4 was characterised (85, 86). The L6 rat muscle cell culture were started, grown and
differentiated (see figure 3.0.1) as described in the ‘Materials and methods’-chapter.
3.1 RT-PCR
3.1.1 Expression of genes involved in lipid metabolism
Previous experiments conducted at the Garvan Institute of Medical Research, Sydney, Australia
have shown that rats fed a high fat diet have a significant increased FAT/CD36 (1.5 fold) and
FATP (8.5 fold) mRNA gene expression in muscle (red gastroc) compared to chow fed rats.
FATP
To test whether this also applies in v tro the relative FATP mRNA expression was measured in
24 and 48 hour incubated L6 rat muscle cells by quantitative RT-PCR. Surprisingly, the result
showed that there was no significant change in FATP expression between the different
treatments and their controls, either after neither 24- nor 48-h incubation. To obtain easily
detectable PCR cDNA products, the FATP samples were ran at 38 cycles. This may indicate that
the FATP gene is not very abundantly expressed in L6 rat muscle cells.
Figure 3.0.1 Differentiated L6 rat muscle cells
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CD36/FAT
Attempts with several different, previously tested CD36/FAT primers under several different
conditions did not give any PCR product. This raised doubt as to whether CD36/FAT is
expressed in L6 rat muscle cells. The expression of CD36/FAT was further investigated using
real-time PCR (LightCycler) without formation of a PCR product.
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Figure 3.1.2.1 Visualisation of FATP (Fatty
Acid Transport Protein), DNA b.p.(DNA
binding protein), IKK and NFk B gene
expression in L6 rat muscle cells
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3.1.2 Expression of genes involved in stress related pathways
IKK
IKK b  is, involved in the activation of the oxidative stress responsive transcription-factor NFk B.
Although the density measured shows some variation, the IKKb  gene xpression was not
significantly changed by linoleate treatment or any of the other treatments (n=2, figure 3.1.2.1). 
NF B
NFk B is reported to be activated by degradation of the inhibitory sub-unit Ik B. Several stimuli,
including increased oxidative stress are known to activate NFk B, which, upon activation
translocates into the cell nucleus and initiates gene transcription. The RT-PCR results did not
show any significant change in gene in NFk B gene expression in any of the treatments compared
to their controls.
0
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0.06
0.08
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0.12
Figure 3.1.2.1
Cyclophillin corrected IKK gene
expression in L6 rat muscle cells
C, Control; L, Linoleate treated;
R, Rosiglitazone;
TNF, tumor necrosis
factor-a
n=2
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cJun
c-Jun, a member of the bZIP protein family, can form hetrodimers with other proteins, including
cFos. After dimerisation it can bind to DNA and initiate transcription. cJun is activated by an
upstream signal delivered by the Jun N-terminal kinase (JNK) (87).
Microarray expression analysis conducted at the Garvan Institute of Medical Research showed
that cJun was upregulated by >2-fold in rats fed a high-fat diet compared to chow fed rats.
The results from quantitative RT-PCR measurements show that the c-Jun mRNA expression in
L6 rat muscle cells was not significantly affected by 1mM linoleate treatment or any of the other
treatments compared to their controls.(figure 3.1.2.2)
dbp
The gene expression of DNA-binding protein, a transcription factor, that previously has been
shown to increase by 5 fold in high-fat fed rat muscle, did not increase in L6 cells after linoleate
incubation or in any of the other treatments (data not shown).
Figure 3.1.2.2
Cyclophilllin corrected
c-Jun gene expression in
L6 rat muscle cells
C, Control; L, Linoleate
treated; R,
Rosiglitazone.
TNF, tumor necrosis
factor-a .
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3.1.3 Positive control
UCP3
Uncoupling Protein-3 (UCP3) mRNA has been reported to be upregulated in 24-h fatty acid
treated L6 myotubes (88, 89), an effect reported not to be reversed by rosiglitazone, and was
used as a positive control.
The PCR results (figure 3.1.3.1 and figure 3.1.3.2) showed that the linoleate treatment increased
UCP3 mRNA expression significantly by 2 fold after 48 h incubation (n=4, p=0.0067) and close
to a significant by 4.5 fold (n=4, p=0.058) after 24 h treatment. The increase was confirmed by
real-time PCR (see LightCycler). Linoleate treatment also significantly upregulated UCP3 gene
expression by >2 fold in rosiglitazone treated L6 cells (n=4, p=0.024) after 48 hours. This
confirms that the linoleate treatment has had an impact on cultured L6 cells.
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Figure 3.1.3.1
Positive control, Cyclophillin
corrected UCP3 gene expression
in L6 rat muscle cells
after 1mM linoleate treatment.
C, Contol; L, Linoleate; R,
Rosiglitazone 2*10-7M.
n=4
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3.1.4 Real-time-PCR (LightCycler)
Real-time PCR measurements were conducted to confirm the RT-PCR results that showed an up-
regulation in UCP3 gene expression in L6 muscle cells after 1mM linoleate treatment (see
section 3.1.3). The LightCycler results showed a highly significant increase in UCP3 gene
expression in L6 cells after both 24- and 48-h linoleate incubation, although a high cycle number
indicates that UCP3 probably is not very highly expressed in L6 rat muscle cells.
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Figure 3.1.4.1
UCP3 gene expression in L6
rat muscle cells. Real time
PCR (LightCycler)
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Figure 3.1.3.2
UCP3 RT-PCR product visualised on a
1.5% agarose gel
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3.2 Micro array gene expression analysis
Control and 24-h linoleate treated total mRNA from five experiments were pooled, processed
according to the AffymetrixÔ  protocol as described in the ‘Methods and materials’, and
analysed using two AffymetrixÔ  U34A GeneChips.
Both gene chips showed an acceptable background noise, and all housekeeping mRNA controls
and added mRNA controls were present with an acceptable 3’/5’ ratio which indicates good
starting mRNA quality and reliable results.
The Micro Array SuiteÔ  (MAS) v5 software measured, by probability algorithms, that 4061 out
of 8784 probe sets where present in the linoleate chip, and that 4196 probe sets were present in
the control-chip. When data from the two chips were compared, MAS5 calculated that the
linoleate treatment upregulated 358 probe sets and down-regulated 310 whereas 19 were
marginally increased and 12 marginally decreased.
As shown in figure 3.2.1, the magnitude of the change is widely distributed, with the majority
(>85%) of the probe sets changing two fold or less, and more than half of the probe sets
changing only 1.3 fold or less.
Distribution in gene expression change
Linoleate vs control treatment
1.1-1.3 1.4-1.5 1.6-2 2.1-2.5 2.6-3 3.1-5 >5
Fold change
Down-regulated
Up-regulated
Figure 3.2.1
Distribution in the magnitude of
change in gene expression
between linoleate treated and
control L6 rat muscle cells
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The magnitude of the change is presented in fold-change. This unit can sometimes, especially at
low abundances be a misleading measurement of change, and signal intensity is therefore
included in the tables.
There are >1000 probe sets on the U34A GeneChip, called expressed sequence tags (ESTs),
which represent unknown genes. Around 190 ESTs were up- or down regulated when the two
chips were compared and these were, although included in the appendix (Appendix II), excluded
from further analysis.
Some of the genes that changed are commented on below. The complete list of probe sets that
showed an altered expression between the linoleate treated L6 rat muscle cells and the control
are included in ‘Appendix I’.
3.2.1. Genes involved in lipid metabolism
The expression microarray data showed that several probe sets encoding for genes involved in
lipid metabolism changed with linoleate treatment. Genes involved in lipid degradation (b -
oxidation) such as acyl-CoA acyltransferase 2 and acyl-CoA dehydrogenase, showed as expected
an overall increased expression. Some of these genes are presented in table 3.2.1.1 (illustrated in
figure 3.2.1.1).
GENE_ID NAME Fold ch Sig. Lin. Sig. Con Swissprot
L07736 carnitine palmitoyltransferase 1 4.6 198 40 P32198
X05341_at acetyl-Coenzyme A acyltransferase 2 1.7 343.3 177.5
 (mitochondrial 3-oxoacyl-Coenzyme A thiolase)
J02791 acetyl-coenzyme A dehydrogenase, medium chain 1.2 236 171 P08503
J05029_s_at acetyl-Coenzyme A dehydrogenase, long-chain 1.6 262.7 152.9 P10608
rc_AA893242 fatty acid Coenzyme A ligase, long chain 2 -1.3 72 101 P18163
D30666 fatty acid Coenzyme A ligase, long chain 3 -1.5 675 1105 Q63151
D85189 fatty acid Coenzyme A ligase, long chain 4 -1.3 326 430 O35547
rc_AI236284 fatty acid Coenzyme A ligase, long chain 4 -1.3 137 209 O35547
Genes involved in ATP-production, including ATP-synthase (gene id AA799778, increased 13
fold) were generally increased in L6 cells after linoleate incubation.
Table 3.2.1.1 Genes involved in lipid activation and b -oxidation:
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GENE_ID NAME Fold ch Sig. Lin. Sig. Con Swissprot
J05210 ATP citrate lyase -1.5 200 321 P16638
J05210 ATP citrate lyase -1.3 574 740 P16638
rc_AA892832 fatty acid elongase 1 -1.1 724 Q920L7
X13527cds fatty acid synthase -1.2 397 505 P12785
Surprisingly, expression of CPT1, the enzyme transporting acyl-CoA into the mitochondrion, did
not change for the muscle isoform (CPT1b), whereas linoleate treatment upregulated expression
of the liver CPT1a isoform in L6 cells more than 4 fold. On the other hand, expression of genes
involved in de novo fatty acid synthesis, including ATP citrate lyase and fatty acid synthase were
generally slightly decreased after linoleate incubation (see table 3.2.1.2).
GENE_ID NAME Fold ch Sig. Lin. Sig. Con Swissprot
D45252 2,3-oxidosqualene: lanosterol cyclase -1.3 68 86 P48450  
rc_AI171090 3-hydroxy-3-methylglutaryl CoA lyase 1.9 84 54 P97519
M29249cds 3-hydroxy-3-methylglutaryl-Coenzyme A reductase -1.9 30 67 P51639
X55286 3-hydroxy-3-methylglutaryl-Coenzyme A reductase -1.7 22 51 P51639
X52625 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 -1.9 450 805 P17425
rc_AI177004 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 -2.3 193 439 P17425
AB016800 7-dehydrocholesterol reductase -1.7 121 160 Q9Z2Z8
AB016800 7-dehydrocholesterol reductase -1.5 146 199 Q9Z2Z8
M89945mRNA farensyl diphosphate synthase -1.9 572 1261 P05369
rc_AI180442 farensyl diphosphate synthase -2.3 208 471 P05369
M89945mRNA farensyl diphosphate synthase -1.7 639 1113
M95591 farnesyl diphosphate farnesyl transferase 1 -1.9 247 393 Q02769
M95591 farnesyl diphosphate farnesyl transferase 1 -1.9 150 223 Q02769
AF003835 isopentenyl-diphosphate delta isomerase -2.1 80 203 O35760
M29472 mevalonate kinase 1.3 87 88 P17256
rc_AA924198 mevalonate kinase -1.5 77 118 P17256
D37920 squalene epoxidase -1.4 249 361 P52020
Table 3.2.1.2 Genes involved in lipid synthesis:
Table 3.2.1.3 Genes involved in cholesterol biosynthesis:
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Several genes involved in cholesterol synthesis were, as illustrated in figure 3.2.1.2, abundantly
present and decreased after linoleate treatment. The expression of the LDL-receptor was also
reduced with linoleate incubation. These observations are discussed in more detail in the
discussion chapter.
The microarray results showed that FAT/CD36 mRNA was absent in L6 rat muscle cells. This
explains why the conducted RT-PCR and real-time-RT-PCR did not give any PCR product.
Figure  3.2.1.1 Changes in expression of genes involved in fatty acid degradation.
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3.2.2 Genes involved in insulin signalling:
Table 3.2.2.1
Gene ID Name Sign. Con. Sign. Lin. Fold change Swissprot
X58375_at Insulin receptor substrate 1 36.9 24.7 -1.4 P14423
rc_AI105076_s_atMurine thymoma viral (v-akt)- 120.5 86.6 -1.3 P48317
 oncogene homolog 2
Although not a large change, expression of insulin receptor substrate 1(IRS1) and Protein Kinase
B beta (PKB beta/v-akt2) both important in insulin signalling changed with linoleate incubation
Figure 3.2.1.2 Changes in expression of genes involved in cholesterol biosynthesis in L6 rat muscle cells
after linoleate incubation.
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(figure 1.2.1 in the introduction chapter). Mice lacking the IRS1 are insulin resistant (90), and
recently it has been demonstrated that mice lacking the PKB beta gene exhibit mild growth
deficiency and are insulin resistant. (91)
3.2.3 Genes involved in oxidative-stress-protection:
Table 3.2.3.1
Gene ID Name Sign. Con Sign. Lin. Fold ch Swissprot
M11670_at Catalase 71.6 84.7 1.1 Q923V7
rc_AA926149_g_atCatalase 127.5 138 1.2 Q923V7
X60328_g_at cytosolic epoxide hydrolase 52.8 64.8 1.3
X12367cds_s_atGluathione peroxidase 1 1626.2 1439.1 -1.1 O35823
J02679_s_at NAD(P)H dehydrogenase, quinone 1 1536.9 1980 1.3
As shown in table 3.2.3.1, both catalase and gluthatione peroxidase play an important role in
protecting the cell against oxidative stress. The microarray results show that catalase is slightly
increased in the linoleate treated L6 cells, whereas the gluthatione peroxidase 1 gene expression
is slightly decreased. Cytosolic epoxide hydrolase and quione 1 are also involved in protection
against oxidative stress.
3.2.4 Genes involved in stress associated signalling:
Table 3.2.4.1:
Gene ID Name Sign. Con Sign. Lin. Fold ch Swissprot
AJ000557cds_s_atJanus kinase 2 (a protein tyrosine kinase) 78.2 49 -1.2 O35804 
U13396_at Janus kinase 2 (a protein tyrosine kinase) 111.2 59.8 -1.5 P49088
U13396_g_at Janus kinase 2 (a protein tyrosine kinase) 120.2 95.8 -1.3 Q62651
rc_AI171630_s_atmitogen activated protein kinase 14 190.6 278.5 1.3 P16232 
U73142_g_at mitogen activated protein kinase 14 188.7 244.3 1.2 O35854
rc_AI178835_atmitogen activated protein kinase kinase 1 25.7 11.3 -1.9 O35532
U35345_s_at p21 (CDKN1A)-activated kinase 2 56.3 40.7 -1.3 Q8VHU3
U42627_at dual specificity phosphatase 6 159.2 209.6 1.3 Q62784
X94185cds_s_atdual specificity phosphatase 6 94.5 122.6 1.3 P18916
Expression of several genes involved in stress associated signalling pathways were altered in L6
cells after linoleate incubation. Some of these are included in the table above. Janus kinase 2
(JAK2) is a protein involved in the stress sensitive JAK/STAT pathway. There are three probe
sets for the JAK2 gene on the U34A rat gene chip, and the fact that all of them show a slightly
decreased expression adds to the reliability of the result. Mitogen activated protein kinase
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(MAPK) 14 (also known as MAPK p38) is a member of the MAP serine/threonine protein
kinases and is known to be a stress activated protein. Activation of MAPK 14 has been reported
to cause inhibition of insulin mediated glucose transport in L6 cells (92). MAPK 14 expression
was slightly upregulated in the L6 cells after linoleate incubation, whereas mitogen activated
protein kinase kinase 1, a protein in the same pathway was down regulated. The dual specificity
phosphatase 6 deactivates MAP kinases, with specificity for the ERK family (106).
3.2.5 Genes involved in cytokine pathways:
Table 3.2.5.1:
Gene ID Name Sign. Con Sign. Lin. Fold ch Swissprot
AJ012603UTR#1_ata disintegrin and metalloproteinase dom 17 100 118 1.2
M26744_at Interleukin 6 (interferon, beta 2) 39.5 33.8 -1.3 P06536
rc_AI237535_s_atLPS-induced TNF-alpha factor 283 238.3 -1.2 Q00918
X17053cds_s_atsmall inducible cytokine A2 143.9 221.4 1.5
X17053mRNA_s_atsmall inducible cytokine A2 261.9 432 1.5
LPS-induced TNF-alpha factor may have a role in regulating the transcription of TNFa  (107)
whereas a disintegrin and metalloproteinase domain 17, also known as TNF-alpha convertase,
cleaves the membrane-bound precursor of TNFa  t  its mature soluble form.
Interleukin 6 changed in the L6 mRNA expression comparison, is a cytokine with a wide array
of effects. Small incucible cytokine A2 is a chemotaktic factor that atracts monocytes but not
neutrophiles.
3.2.6 Genes involved in gene transcription:
Gene expression of several transcription factors both involved in initiation and inhibition of gene
transcription was increased with linoleate treatment. Some of these are included in the list below.
Two genes (Kruppel-like factor 9 and immediate early transcription factor) are represented by
two probe sets.
CCAAT/enhancer binding protein-d  (C/EBP-d ) was also increased (1.7 fold) after linoleate
incubation. This transcription factor is a member of the bZIP family and is thought to be
important in adipocyte development. Cells with C/EBP-d  deficiency has been shown have
reduced IRS-2 and GLUT4 expression (108).
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Table 3.2.6.1 Genes involved in gene transcription:
Gene ID Name Sig.Con Sig.Lin. Fld ch Swissprot
rc_AA946292 CCAAT/enhancerbinding, protein (C/EBP) delta 41 59 1.7 Q01713
rc_AA800912 general transcription factor II I repeat domain-containing 1 97 82 -1.2 P41138
rc_AA944177 high mobility group box 1 19 23 1.2 Q01713
rc_AI029805 high mobility group box 1 18 79 3.2 P19335
U17254 immediate early gene transcription factor NGFI-B 33 49 1.5 Q63046
U17254 immediate early gene transcription factor NGFI-B 22 79 3.5 Q62655
L23148 Inhibitor of DNA binding 1, helix-loop-helix protein (splice variation) 22 32 1.5 AAF82799
rc_AI230256 Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein 55 68 1.2 Q9R0W1
rc_AI171268 Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein 24 98 2.8 O70185
D12769 Kruppel-like factor 9 46 62 1.3
D12769 Kruppel-like factor 9 205 272 1.3 AAF82799
M27151 myogenic factor 6 13 25 1.6 P41137
rc_AI176488 nuclear factor I/B 56 65 1.1 O70189
AB012234 nuclear factor I/X 73 87 1.4 Q03484
M14053 nuclear receptor subfamily 3, group C, member 1 27 36 1.3 P41135
AF039832 paired-like homeodomain transcription factor 2 879 996 1.2 AAO32676
rc_AI180396 Retinoblastoma-related gene 94 107 1.2 P06536
rc_AI230602 Retinoblastoma-related gene 158 274 1.7 O55081
L35271 Runt related transcription factor 1 617 736 1.1 P22829
U09228 transcription factor 4 105 77 -1.3 O55081
U51583 transcription factor 8 83 173 1.4 Q08013
Z14030 TRAP-complex gamma subunit 47 200 3.5 P97659
U56242 v-maf musculoaponeurotic fibrosarcoma (avian) oncogene homolog (c-maf) 86 68 -1.2 P54844
U27186 zinc finger protein 111 65 73 1.2 Q62947
L16995_at ADD1/sterol regulatory element binding factor 1 170.3 73 -2.5
3.2.7 Genes involved in intracellular signalling:
Several of the probe sets that showed a changed gene expression in L6 cells after linoleate
treatment are involved in intracellular signalling, and some of these are presented in table
3.2.7.1. Several of these genes where changed in two or more probe sets (including myristoylated
alanine rich protein kinase C substrate, noggin, RAB11B and protein phosphatase 2C). Although
the probe sets in table 3.2.7.1 represents genes involved in several different pathways, some of
the genes are involved in the same pathway. Noggin, JAK2 (see figure 3.2.4.1), bone
morphogenetic protein receptor (type 1A) and MAD homolog 1, 2 and 4 are all involved in
transforming growth factor-b  signalling pathway.  Transforming growth factor beta 3 and
TGFbb  Inducible Early Growth Response gene expression also changed after linoleate treatment
(see Appendix I).
Other interesting genes that changed expression in L6 cells include prostaglandine-endoperoxide
synthase 2 (COX-2), ras-related protein rab10 and the chemokine orphan receptor 1, also known
as calcitonin/calcitonin-related polypeptide, alpha.
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Table 3.2.7.1 Genes involved in intracellular signalling:
Gene ID Name Sign.con Sign. Lin.F.ch Swissprot
Y15748_at 3-phosphoinositide dependent protein kinase-1 53.7 39.1 1.4 O55173
M77850_at 6-pyruvoyl-tetrahydropterin synthase 148.9 6.7 12.1 P27213
U94904_s_at abl-interactor 2 140.6 118.5 1.2 O35823
rc_AI176052_atadenylate kinase 3 635 778.3 -1.1 P29411
M80550_at adenylyl cyclase 2 416.9 340 1.1 P26769
rc_AA946251_atG protein-coupled receptor kinase 5 27.9 14.3 1.4 Q62833
U26397_at inositol polyphosphate-4-phosphatase, type 1 106.6 90.2 1.1 Q62784
AF067727_s_atMAD homolog 1 (Drosophila) 24.9 39.6 -1.4 P97588
AB017912_at MAD homolog 2 (Drosophila) 184.4 245.3 -1.1 O70436
rc_AI228675_atMAD homolog 2 (Drosophila) 26.4 37.8 -1.5 O70436
rc_AI008639_atMAD homolog 4 (Drosophila) 91.3 22.1 3.2 O70437
rc_AA899253_atmyristoylated alanine rich protein kinase C substrate 319.9 393 -1.2 P30009
rc_AA925762_atmyristoylated alanine rich protein kinase C substrate 63.5 70.7 -1.2 P30009
rc_AA955167_s_atmyristoylated alanine rich protein kinase C substrate 93.7 107.9 -1.2 P30009
rc_AA859752_atNoggin 21.9 31.5 -1.4 Q62809
U31203_at Noggin 95.1 109.9 -1.2 Q62809
D64046_at phosphatidylinositol 3-kinase, regulatory subunit, 56.1 48.6 1.2 Q63788
 polypeptide 2
D64046_g_at phosphatidylinositol 3-kinase, regulatory subunit,pp2 76.6 19.8 3.7 Q63788
D88666_at phosphatidylserine-specific phospholipase A1 432.9 302.3 1.4 P97535
X51529_at phospholipase A2, group IIA (platelets, synovial fluid) 46.9 28.6 1.4 P14423
rc_AA998446_s_atphosphotidylinositol transfer protein, beta 177.9 242 -1.2 P53812
S67722_s_at prostaglandin-endoperoxide synthase 2 35.2 68.5 -1.9 P35355
U63740_at protein kinase C-binding protein Zeta1 15.6 39.3 -2.0 P97577
D26180_at protein kinase C-like 1 40.8 24.1 1.9 Q63433
M12492mRNA#1_atprotein kinase, cAMP dependent regulatory, type II beta 124.8 89.3 1.3 P12369
M12492mRNA#1_g_atprotein kinase, cAMP dependent regulatory, type II beta 36.1 9.2 3.5 P12369
S78218_at Protein phosphatase 1, catalytic subunit, beta isoform 1294.4 810.1 1.5 P37140
AF095927_at protein phosphatase 2C 116.5 86.8 1.2 Q9Z1Z6
AF095927_g_atprotein phosphatase 2C 195.1 153.7 1.2 Q9Z1Z6
rc_AA799980_atProtein phosphatase type 1B (formely 2C), 284.6 317.5 -1.1 CAC28067
Mg-dependent, beta isoform
D01046_at RAB11B, member RAS oncogene family 278 245.7 1.1 O35509
AA891669 RAB11B, member RAS oncogene family 685 502 1.3 O35509
X06889cds_at RAB3A, member RAS oncogene family 63.2 30.5 2.1 P05713
rc_AA851381 Ras homolog enriched in brain 45.2 9.6 3.0 Q62639
rc_AA851381_atRas homolog enriched in brain 45 10 3  Q62639
rc_AA955306_atras-related protein rab10 631.2 216.1 2.8 P35281
AF035151_s_atregulator of G-protein signaling 12 608 431.7 1.3 O08774
AF084205_at serine/threonine protein kinase TAO1 101.4 126.1 -1.2 O88664
U90312 Synaptojanin II 104 86 1.2
It is worth noting that 6 pyruvoyl-tetrahydropterin synthase, an enzyme involved in the de ovo
synthesis of 5,6,7,8 tetrahydrobiopterin (BH4), and thereby indirectly involved in signalling, was
switched on by linoleate incunbation (12 fold increase, signal intensity 6.7 to 148). BH4 is a
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cofactor for several enzymes including the aromatic amino acid hyrdroxylases and tyrosine 3-
monooxygenase and is also involved in the synthesis of NO.
3.2.8 Genes involved in transport:
Several probe sets encoding for genes involved in transport changed with linoleate treatment in
L6 muscle cells. Some of them are included in table 3.2.7.1
Probe_set name Sig. Con Sig.Lin F.Ch Swisprot
rc_AA859975_at 2-oxoglutarate carrier 371.4 447.3 1.1 O70603
rc_AA799778_at ATP synthase, H+ transporting, mitochondrial 99.6 1523.8 13.0 Q9Z2J3
M99223_at ATPase, Ca++ transporting, cardiac muscle, 61.5 119.6 1.5 P31232
fast twitch 1
AA799276_at ATPase, Ca++ transporting, cardiac muscle, 1443.5 1708.1 1.1               
slow twitch 2
M86621_at calcium channel,voltage-dependent, alpha2/delta s.u.1 189.1 246.7 1.3  P26769
L07736_at carnitine palmitoyltransferase 1 39.9 198 4.6 P09057
rc_AA799645_g_at FXYD domain-containing ion transport regulator 1 32.7 78.6 1.7 P16632
rc_AA799645_at FXYD domain-containing ion transport regulator 1 167.3 187.5 1.2 P54290
X66494_at integrin alpha 7 110.7 158.4 1.3  P80299
rc_AA892810_at low density lipoprotein receptor-related protein 67.8 78.9 1.1 P20294
 associated protein 1
rc_AA891045_at nucleoporin p58 12.1 15.9 1.2 P28480
U69884_at potassium intermediate/small conductance 18.6 28.9 1.5 Q62981
rc_AA799760_s_at solute carrier family 2 , member 4 10 39.6 3.2
S68135_s_at solute carrier family 2,member 1 75.1 32.7 -2.1
D12770_s_at solute carrier family 25 (mitochondrial adenine 1845.3 2183.3 1.2 Q01713
translocator) member 4
rc_AA892776_at solute carrier family 25 (mitochondrial carrier; adenine 939.7 2066.7 1.5 Q99MI5
adenine nucleotide translocator), member 3
U70476_at solute carrier family 7, member 1 154.1 120.1 -1.2 P70565
rc_AA800787_at Transferrin 702.8 559.8 -1.2  
Both solute carrier family 2 member 1 (GLUT1) and member 4 (GLUT4) changed in expression
after linoleate incubation. The abundance of both these transporters is remarkably low. This
gives less confidence in the magnitude of the change, and the low expression of these vital
transporters also questions the glucose transporting proparlies of the L6 cell.
Table 3.2.8.1 Genes involved in transport.
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3.2.9 Combined search, muscle:
As described in ‘Methods and materials', a combined search was conducted on microarray data
from two experiments comparing gene expression in muscle between high-fat-fed rats and chow
fed rats and the comparison between linoleate treated and control L6 muscle cells. This search
revealed that 11 probe sets showed increased gene expression and 3 probe sets showed a
decrease in all three comparisons, representing a total of 12 genes.
Of these 10 represent known genes and 2 unknown genes (presented in table 3.2.8.1). Of the 16
known genes, two genes, v-jun and immediate early gene transcription factor NGFI-B increased
in two probe sets. V-jun differs from the related c-jun by a 27-amino acid deletion near the N-
terminus and can not, unlike c-jun, be activated by upstream JNK signalling. V-jun belongs to
the ‘bZIP’ proteins, and can form homodimers and heterodimers with various other ‘bZIP’
proteins, including c-fos, which can lead to regulation of transcription (87). NGFI-B is a nuclear
receptor with structural features of ligand-activated transcriptional regulators, and together with
Nurr1 and NOR-1 forms the NGFI-B superfamily. No specific ligands have been identified for
Changed high-fat-fed vs
chow fed rat muscle
experiment 1
Changed high-fat-fed
vs chow fed rat muscle
experiment 2
Changed linoleate
treated vs control L6
rat muscle cells
No. probe sets with
changed gene expression:
-Increased: 11
-Decreased: 3
Figure 3.2.8.1
Illustration of combined gen-chip-
data search
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these receptors (93). Another interesting gene that decreased in expression both in rat muscle and
in cultured cells is the insulin receptor substrate-1 (IRS1). IRS1 is involved in insulin signalling.
Acetyl-CoA acyltransferase 2 is a key enzyme in b -oxidation of fatty acids and is, as expected,
increased after increased lipid exposure. Early growth response 1, a member of the zinc finger
transcription-factor family, has recently been reported to be regulated by insulin (109).
Table 3.2.8.1 Probe sets showing a change in expression after lipid exposure in both red gastroc rat muscle tissue
and L6 rat muscle cells:
Muscle1 Muscle2 L6
Gene ID Name (f-ch) (f-ch) (f-ch) swissprot
X05341 acetyl-Coenzyme A acyltransferase 2 1.6 1.5 1.7  P13437
(mitochondrial 3-oxoacyl-Coenzyme A thiolase)
rc_AA866452 actin alpha  cardiac 1 -1.3 -1.3 -1.2 P03996
AF009329 basic helix-loop-helix domain containing, class B3 1.9 1.6 1.1 O35779
M18416 early growth response 1 2 1.6 1.4 P08154
U08976 enoyl coenzyme A hydratase 1 1.7 1.6 1.5 Q62651
U17254 immediate early gene transcription factor NGFI-B 2.1 1.7 1.5 P22829
U17254 immediate early gene transcription factor NGFI-B 3.5 2 1.7 P22829
X58375 Insulin receptor substrate 1 -1.9 -1.6 -1.4 P35570
D00729 Rattus norvegicus mRNA for 1.9 1.6 2.6 Q64592
delta3, delta2-enoyl-CoA isomerase, complete cds
rc_AA945867 v-jun sarcoma virus 17 oncogene homolog (avian) 1.6 2.5 1.2
rc_AI175959 v-jun sarcoma virus 17 oncogene homolog (avian) 1.4 1.9 1.1
X06801cds Rat mRNA for vaskular alpha-actin -2.1 -1.9 -1.2
3.2.10 Combined search, liver:
Compared to the control, the micro array data from linoleate treated L6 showed that genes
involved in lipid synthesis (figure 3.2.1.1) and cholesterol biosynthesis (figure 3.2.1.2) were
abundantly expressed in L6 cells. The data also revealed that mRNA expression of CPT1, liver
isoform, and not the muscle isoform, increased after 1mM linoleate incubation. Based on this, a
combined search where conducted on microarray data from two experiments comparing gene
expression in liver from high-fat-fed- and chow-fed rats, and the comparison between linoleate
treated and control L6 rat muscle cells.
This combined search showed that 18 common genes were increased and 19 were decreased in
all three comparisons, encoding for a total of 34 known genes. Several genes involved in fatty
acid synthesis where increased in all comparisons (including ATP-citrate lyase), and several
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genes involved in b -oxidation (such as CPT1, liver isophorm and acyl-CoA dehydrogenase) and
cholesterol synthesis were decreased (such as 7-cholesterol reductase).
Other genes of interest include the glucocoriticoid receptor (also known as nuclear receptor
subfamily 3, group C, member 1), kruppel-like factor 9 (also known as basic transcription
element binding protein, (BTEB)) and the insulin-induced growth response protein (CL-6) (94).
Table 3.2.9.1 Probe sets showing a change in expression after lipid exposure in both rat liver and L6 rat muscle
cells:
Gene ID Name Swissprot Liver#1 Liver#2 L6
AB016800 7-dehydrocholesterol reductase  Q9Z2Z8 -1.6 -1.6 -1.7
AB016800 7-dehydrocholesterol reductase Q9Z2Z8 -1.5 -1.7 -1.5
J05029 acetyl-Coenzyme A dehydrogenase, P15650 1.5 1.7 1.6
long-chain
J05210 ATP citrate lyase P16638 -2.3 -1.4 -1.5
J05210 ATP citrate lyase P16638 -1.9 -1.7 -1.3
L07736 carnitine palmitoyltransferase 1 P32198 2.3 2.5 4.6
rc_AI237535 cysteine rich protein 1 -1.9 -1.9 -1.2
X13527cds DnaJ-like protein P12785 -2.0 -3.2 -1.2
U53922 dual specificity phosphatase 6 P54102 1.3 1.3 1.1
U08976 Eonyl coA hydratase 1 1.9 1.9 1.5
L13619 growth response protein (CL-6) Q08755 -2.0 -1.9 -2.5
L13619 growth response protein (CL-6) Q08755 -1.6 -1.6 -2.1
D12769 Kruppel-like factor 9 Q01713 2.0 1.7 1.3
D12769 Kruppel-like factor 9 Q01713 2.0 1.7 1.3
rc_AA946108 laminin 5 alpha 3 P70570 1.7 2.3 2.1
S45663 LPS-induced TNF-alpha factor -1.1 -1.3 -1.2
M63485 matrin 3 P43244 1.3 1.7 2.1
rc_AI102562 Metallothionein P02803                      1.4 1.6 1.4
M14053 nuclear receptor subfamily 3, group C, m1 P06536 4.6 1.9 1.3
D00729 Rattus norvegicus mRNA for delta3, Q64592 2.3 2.5 2.6
delta2-enoyl-CoA isomerase, complete cds
J02585 stearoyl-Coenzyme A desaturase 1 P07308                         -168.9 -48.5 -4.0
rc_AI175764 stearoyl-Coenzyme A desaturase 1 P07308                        -22.6 -222.9 -4.6
AF036761 stearoyl-Coenzyme A desaturase 2 O54953                          -18.4 -52.0 -3.5
U42627 synaptic glycoprotein SC2 Q64346 1.6 1.7 1.3
rc_AI176456 Transcribed sequence with strong similarity to 2.8 2.5 1.1
 METALLOTHIONEIN-II (MT-II)
rc_AA945867 v-jun sarcoma virus 17 oncogene homolog (avian) 2.5 2.3 1.2
rc_AI175959 v-jun sarcoma virus 17 oncogene homolog (avian) 1.9 1.9 1.1
L16995 Add1 -1.2 -1.6 -2.5
4. DISCUSSION
Although the link between increased lipid muscle content and insulin resistance is well
established, the mechanisms behind this association are still not fully understood.
Gene array experiments on rat muscle tissue performed by the Diabetes group at the Garvan
Institute of Medical Research, revealed that high-fat feeding increased expression of genes
involved in stress associated pathways (such as c-jun, NFk B a d IKK). Some of these genes
have been linked to mechanisms involved in the development of insulin resistance (55-57). As
discussed in the introduction chapter, some genes involved in providing cellular protection
against oxidative stress are down regulated in skeletal muscle in people with type-2 diabetes,
suggesting that oxidative stress has a role in development of the disease.
It is not known whether the increase in muscular expression of stress-genes observed in rats is a
direct consequence of elevated muscular exposure to fatty acids, or whether the increased
expression is a secondary effect of the high-fat diet. This change could for instance be due to an
increase or decrease in secretion of a hormone by tissue other than muscle with an effect on
skeletal muscle.
The main purpose of the study performed here was to use an in vitro rat muscle system to see if
the in vivo effects of a high linoleate diet could be mimicked in vitro.
4.1 RT-PCR results
In this study, the relative expression of some genes involved in stress sensitive signalling was
first measured in L6 rat muscle cells by conventional RT-PCR, after linoleate treatment.
Transcripts of NFk B, IKK, c-jun were detected and abundantly expressed in all samples
(measured at 29, 26 and 28 cycles respectively). The results revealed that neither c-jun, NFk B or
IKK were significantly upregulated by 24 or 48-h 1mM linoleate incubation in differentiated L6
rat muscle cells, although there was a tendency for NFk B to be up-regulated by linoleate after
48-hour incubation. DNA binding protein, previously reported to be upregulated by >5 fold by
high-fat feeding in rat muscle in vitro was also measured in L6 cells by RT-PCR. The result
revealed that linoleate did not significantly change the gene expression of DNA binding protein
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compared to control.
Surprisingly, TNF-a , reported to increase oxidative stress and stress associated gene expression
in cultured skeletal muscle models, did not have an impact on the measured stress-related genes
in L6 cells (100, 101). Also, the PPAR agonist rosiglitazone did not have any effect on the
measured stress related gene expression. Rosiglitazone has previously, been demonstrated by the
Diabetes Group at the Garvan Institute to reverse increased stress-related gene expression in
high-fat-fed rats.
To ensure that the L6 muscle system was suitable for studies of gene expression in response to
fatty acid exposure, we examined the literature for previous reports of genes upregulated by
incubation with linoleate. UCP3 is reported to be upregulated by up to 10 fold in L6 cells
incubated with linoleate, so we measured UCP3 expression in the linoleate treated L6 muscle
cells to ensure that the linoleate had an impact on the cells compared to control. The
conventional RT-PCR and real-time RT-PCR (LightCycler) results showed a convincing
significant increase in expression after linoleate treatment (chapter 3.1.3 and 3.1.4). This
demonstrated that the increase in linoleate concentration did have an impact on gene expression
in L6 rat muscle cells.
Incubation with 1mM linoleate did not increase expression of the measured stress associated
genes compared to control. This suggests that high dietary fat intake does not have a direct effect
on expression of stress-associated genes in rat muscle, but that the observed change in expression
is a secondary effect.
This secondary effect may be due to a change in secretion of a circulating cytokine or hormone
from tissues other than skeletal muscle in response to increased dietary fat intake.
An example on a cytokine involved in energy homeostasis is leptin. Leptin correlates closely
with fasting insulin concentrations and is known to be a marker of obesity and insulin resistance.
Leptin has been reported to be upregulated by increased dietary fat intake, but it is not know
whether leptin has an effect on stress-related gene expression in muscle (102).  Other studies
have shown that central administration of free fatty acids affect peripheral glucose metabolism
independently of leptin (103, 104). This demonstrates that fatty acids can signal nutrient
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availability to the CNS, but it is not known whether CNS can have an effect on stress-associated
signalling in skeletal muscle.
Another explanation as to why no increase in stress-associated gene expression was detected in
L6 rat muscle cells after linoleate exposure, could be that L6 rat muscle cells are substantially
different from rat muscle cells in vivo, and therefore not a good model.
4.2 Gene chip results
To examine the degree of similarity in gene expression between red gastroc rat muscle tissue and
cultured, differentiated L6 rat muscle cells, a micro array global gene expression experiment was
conducted on mRNA pooled from five separate experiments on 24-h 1mM linoleate treated L6
rat muscle cells and their control.
4.2.1 Evaluation of L6 as a model of rat muscle cells in vivo
The data obtained from this global gene expression experiment showed that the linoleate
treatment changed gene expression of several genes, including genes coding for enzymes
involved in lipid metabolism (see table 3.2.1.1 in the result chapter). Unexpectedly, several genes
involved in cholesterol and bile biosynthesis (for example HMG-CoA reductase and farnesyl
diphosphate syntase) and fatty acid synthesis (for example ATP citrate lyse and fatty acid
synthesis) were expressed in L6 rat muscle and were decreased after linoleate incubation.
Expression of genes involved in cholesterol biosynthesis has also previously been demonstrated
in L6 cells by Matzno et. al. (95). Although the mRNA expression level does not necessarily
reflect the level of active protein this expression data clearly suggests that L6 myotubes have
some properties usually associated with liver.
Interestingly, St-Amand et. al.found through serial analysis of gene expression that various
genes, including genes involved in cholesterol synthesis, were differentially expressed in isolated
immobilised skeletal rat muscle compared to control skeletal rat muscle in vivo (96). This may
contribute to the explanation as to why genes involved in cholesterol synthesis are abundantly
expressed in cultured L6 cells and not in rat muscle in vivo.
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The results from the combined micro array search between data from the comparison of fatty
acid treated L6 cells to control, and data from previously conducted experiments on global gene
expression in liver from high-fat fed rats, also show similarities in gene expression changes
between rat liver and L6 cells (for example the kruppel-like factor 9 and the glucocorticoid
receptor). This, combined with the fact that L6 cells have low gene expression of GLUT4, no
gene expression of CD36/FAT, and that they express the liver isoform of the key enzyme CPT1,
may suggest that there is a substantial difference between cultured L6 rat muscle cells and rat
muscle in vivo. This difference has to be accounted for in future in vitro experiments, and since
CD36/FAT is not expressed and GLUT4 barely expressed in L6 cells this is particularly the case
if the cells are to be used to reflect glucose and lipid metabolic pathways of muscle in vivo.
A gene chip experiment generates a lot of data, and all the differences in gene expression
between linoleate treated L6 muscle cells and control will not be discussed here. The next section
will review some linoleate-generated changes in L6 gene expression.
4.2.2 Genes involved in metabolism
Increased expression of genes involved in lipid mitochondrial transport, and b -oxidation suggests
that linoleate has entered the cell and been metabolised. Interestingly, the micro array data
revealed that the FAT/CD36 protein thought to have a central role in facilitated fatty acid
transport is not expressed in L6 rat muscle. There is evidence that the uptake of fatty acids in L6
cells is the sum of passive diffusion plus a saturable component involving one or more protein
structures (97). The finding that FAT/CD36 is not expressed in L6 cells suggests that there is
another, or several other proteins involved in the active fatty acid transport in differentiated L6
rat muscle cells.
ADD1, also known as sterol regulatory element-binding transcription factor 1 (SREBP-1), is
down regulated by 2.8 fold in the linoleate treated L6 cells compared to the control. This
transcriptional activator regulates transcription of genes involved in lipid metabolism, including
sterol biosynthesis (generally reduced after linoleate incubation, see figure 3.2.1.3.), the LDL
receptor gene (reduced by 2.8 fold after linoleate incubation) and fatty acid synthesis (generally
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reduced after linoleate incubation, see figure 3.2.1.2.). ADD1 is abundantly expressed in liver
where it regulates fatty acid and cholesterol synthesis. Regulation of ADD1 occurs at two levels:
transcriptional through a feed-forward loop, and post-transcriptional regulation (105). Insulin is
known to regulate the activity of ADD1 in liver, and the fact that linoleate incubation leads to
down regulation of this transcription factor is another result that may indicate that L6 cells share
some properties normally associated with liver.
Linoleate incubation also had an impact on expression of genes involved in glucose metabolism.
Glycogen phosphorylase (muscle isoform, gene id L10669), a key protein involved in glycogen
breakdown (represented by two probe sets) showed increased gene expression in L6 cells after
linoleate treatment. On the other hand, an enzyme in glycogen synthesis (glycogenin gene id
U96130) is also increased after linoleate treatment, and drawing conclusions about the rate of
glycogen synthesis based on these mRNA expressions observations would only be speculation.
Expression of two genes involved in glucose transport (GLUT1, solute carrier family 2, member
1 and GLUT4, solute carrier family 2, member 4) changed in mRNA expression after linoleate
treatment. However, both genes, especially GLUT4, showed very low abundance in L6 cells.
The micro array data also revealed that several ribosomal proteins (including ribosomal protein
L4, L21, L13, S24, L22, L7a, L9 and S19, see appendix) were upregulated. Some of these
proteins showed a large increase (ribosomal protein L4 gene expression was upregulated by 4.6
fold) This indicates that linoleate incubation also had an impact on protein biosynthesis in L6
cells.
Together these findings demonstrate that 24-hour 1mM linoleate incubation has a wide influence
on expression of genes involved in L6 rat cell metabolism.
4.2.3 Genes involved in stress-protection and stress related signalling
Results from RT-PCR analysis and gene chip data revealed that linoleate did not up-regulate
mRNA expression of the same stress associated genes as previously observed in high-fat rats.
Discussion
63
This does not necessarily mean that these stress proteins were not activated in L6 cells after
linoleate incubation, as NFk B is activated by degradation of the inhibitory unit and c-jun by
phosphorylation, and not primarily via regulation of its transcription.
Some genes involved in cellular oxidative stress protection (including catalase) were increased
after linoleate treatment (see figure 3.2.3.1). This may indicate that the concentration of free
radicals was increased, although gene expression data is insufficient evidence to draw
conclusions about the intracellular free-radical state of the linoleate treated L6 muscle cells.
Linoleate treatment also increased expression of some genes involved in stress sensitive
signalling pathways (Results chapter 3.2.4). Although not all in the same signalling pathway,
some of these stress proteins are known to interact, and cross-talk between pathways including
JAK2 and NFk B signalling cascades has also been reported (98, 99). Some stress-sensitive genes
of special interest include early growth responce-1 (EGR1, also known as Nerve growth factor-
induced gene, increased by 1.4 fold in two probe sets) and v-Jun (also known as NURR77,
increased by an average of 1.2 fold in three probe sets) both involved in regulation of
transcription. EGR1 is a transcriptional regulator which activate the transcription of target genes
whose products are required for mitogenesis and differentiation. EGR1 is induced by several
growth factors. As discussed in the result chapter, v-jun is a leucine rich bZIP protein, which can
form heterodimers or homodimers with other bZIP proteins, including c-fos.
It is interesting to note that v-jun is upregulated in two probe sets, both by linoleate incubation in
L6 and by high-fat feeding in red gastroc rat muscle and by high-fat feeding in liver in vivo.
Although the upregulation is relatively small, the fact that two probe sets encoding for the v-jun
gene in a total of 10 gene chips all showed that v-jun is increased with linoleate incubation/high
fat feeding, gives an increased confidence in the result.
Both EGR-1 and v-jun are relatively newly discovered transcription factors. Their function in
regulating transcription is not fully understood, but they may play an important role in regulating
gene transcription in muscle.
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To compare the effect on gene expression of linoleate incubation on L6 cells with high-fat
feeding on muscle cells in vivo, the data from the L6 gene chip experiment were compared to
previously conducted gene chip experiments on rat muscle.
4.3 Comparison of L6 rat muscle cells with (red gastroc) rat muscle
The comparison between micro array data from cultured L6 and red gastroc rat muscle revealed
that out of the 2734 probe sets present in rat muscle tissue 2476 probe sets were also present in
the L6 cells. 258 probe sets were absent in the L6 cells. This comparison shows that the majority
of the genes expressed in red gastroc rat muscle in vivo are also present in cultured L6 rat muscle
cells in vitro. It is worth noting that a greater number of probe sets (and thus a greater number of
genes) are expressed in L6 cells (4377) compared to red gastroc rat muscle cells in vivo. This
may indicate that L6 cells express a wider range of genes compared to rat muscle cells in vivo.
Another striking overall difference between the gene expression in rat muscle and cultured cells
is the mRNA abundance (the signal) of genes involved in mitochondrial metabolism. The
expression of genes involved in metabolism in the mitochondria is generally significantly lower
in the L6 cells than in the rat muscle (examples include 3-ketoacyl-coA tiolase, medium and long
chain acyl-CoA dehydrogenase and carnitine palmitoyl transferase 2). One explanation for this
difference may be that rat muscle in vivo is more metabolically active and hence has a larger
number of mitochondria and a larger enzyme density compared to L6 cells.
4.4 Comparison of L6 rat muscle cells with rat liver
The data obtained in the gene chip experiment clearly show that L6 myotubes abundantly
expresses genes encoding for proteins normally associated with liver (such as genes involved in
cholesterol biosynthesis and fatty acid synthesis). This observation lead us to comparing gene
chip data from cultured L6 rat muscle cells with global gene expression data obtained from
previous conducted experiments on liver from high-fat fed rats.  The results revealed that out of
the 2791 probe sets present in rat liver in vivo 2204 were also present, and 587 absent in L6 cells
in vitro.  In addition linoleate incubation of L6 cells upregulated expression of several genes also
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upregulated by high fat feeding in rat liver. Some examples are given in table 4.4.1 (see table
3.2.9.1 for complete list).
Table 4.4.1 Examples on genes changed both in L6 cells (in vitro) and in rat liver (in vivo).
Gene ID Name Swissprot Liver#1 Liver#2 L6
J05210 ATP citrate lyase P16638 -2.3 -1.4 -1.5
L13619 growth response protein (CL-6) Q08755 -2.0 -1.9 -2.5
J02585 stearoyl-Coenzyme A desaturase 1P07308                         -168.9 -48.5 -4.0
L16995 Add1 -1.2 -1.6 -2.5
Together, the comparisons of cultured L6 rat muscle cells, rat muscle cells (in vivo) and rat liver
(in vivo) suggest that although L6 rat muscle cells share several properties with red gastroc rat
muscle, they are also significantly different. The results from the comparisons above together
with the results showing that genes involved in cholesterol biosynthesis, fatty acid synthesis and
sterol regulation are abundantly present and decreased with linoleate incubation in L6 cells,
suggests that in addition to properties similar to rat muscle in vivo, c ltured L6 rat muscle cells
also have properties associated with rat liver.
5. CONCLUSION AND FUTURE PERSPECTIVE
Conclusion:
This study has demonstrated that 24 and 48 h linoleate incubation does not induce any of the
measured stress-associated genes in cultured L6 myotubes previously shown to be upregulated
by high-fat feeding in rat skeletal muscle (in vivo).
Global gene expression analysis of L6 rat muscle cells revealed that there is a substantial
difference between rat muscle cells in vivo and cultured L6 cells. Surprisingly, the global
expression data also revealed that L6 myotubes has some properties normally associated with
liver cells. This suggests that the L6 cell may not be a suitable model for further studies on fat-
induced insulin resistance in rat skeletal muscle.
Future perspective:
To investigate the direct influence on stress associated gene expression in rat muscle further
work is necessary to establish a cell-model that reflects lipid-induced insulin resistance in rat
skeletal muscle in vivo. One way to test the direct effect of fatty acid on stress-associated gene
expression could be to use isolated rat muscle (eg soleus or extensor degitorus longus) and
measure gene expression, either by RT-PCR or by micro array after fatty acid incubation.
However, the viability of isolated muscle could be a problem for long term (>6h) incubation with
fatty acids. A primary rat muscle culture (from satellite cells) could also be established and used
as a model for insulin resistance, although this cell-model could take a long time to
grow/differentiate. However, imperfect simulation of perfusion and lack of electrical stimulation
would also make this cell-model an imperfect imitation of rat muscle in vivo.
It would also be interesting to study the changes in lipid metabolism gene expression observed in
fatty acid incubated L6 cells. By repeating the AffymetrixÔ  Gen  Chip experiment on mRNA
from 1mM linoleate incubated L6 cells and control for a shorter interval (for example 8h instead
of 24h) one would be able to investigate the chronology in the gene expression changes imposed
by fatty acid incubation. In this way early transcription factors central in regulating gene
transcription could be identified.
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Probe_set name Sig. Con Sig.Lin F.Ch Swisprot
rc_AA859975_at 2-oxoglutarate carrier 371.4 447.3 1.1                           O70603
rc_AI171090_g_at 3-hydroxy-3-methylglutaryl CoA lyase 54.4 84.4 1.9
X55286_g_at 3-hydroxy-3-methylglutaryl-Coenzyme A reductase 50.5 22.3 -1.7
rc_AI177004_s_at 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 439.4 193.4 -2.3
X52625_at 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 804.5 449.8 -1.9
X97772_at 3-phosphoglycerate dehydrogenase 470.8 400 -1.2                           P25110
Y15748_at 3-phosphoinositide dependent protein kinase-1 39.1 53.7 1.4                           Q63528
M77850_at 6-pyruvoyl-tetrahydropterin synthase 6.7 148.9 12.1                           P19335
U48288_at A-kinase anchoring protein 15.2 678.8 7.5
U94904_s_at abl-interactor 2 118.5 140.6 1.2
X05341_at acetyl-Coenzyme A acyltransferase 2 177.5 343.3 1.7
 (mitochondrial 3-oxoacyl-Coenzyme A thiolase)
J05029_s_at acetyl-Coenzyme A dehydrogenase, long-chain 152.9 262.7 1.6                           P10608
rc_AI070967_g_at Acid nuclear phosphoprotein 32 (leucine rich) 10.8 16.2 1.6
rc_AA866452_s_at actin alpha  cardiac 1 1147.9 902.9 -1.2                           Q8CJH4
rc_AI104567_g_at actin alpha  cardiac 1 896.9 1038.8 1.2
AF083269_at actin related protein 2/3 complex, subunit 1B 840.8 714.6 -1.1                           O88656
U19893_at actinin alpha 4 553.4 433.3 -1.3                           O35804
rc_AA964379_s_at adaptor-related protein complex 2, beta 1 subunit 158 224 1.6
rc_AI146195_at adducin 3, gamma 14.5 32.5 2.1
rc_AI176052_at adenylate kinase 3 778.3 635 -1.1
M80550_at adenylyl cyclase 2 340 416.9 1.1                           P04937
X80130cds_f_at ADP-ribosylation-like 4 807.2 675 -1.1                           Q63355
rc_AA964849_at ADP-ribosyltransferase 1 19.3 115 4.0                           P30009
J03024_at adrenergic receptor, beta 2 100.9 134.1 1.1                           P05982
rc_AA859702_at afadin 9.6 20.9 2.0
U89905_at alpha-methylacyl-CoA racemase 61.6 84.2 1.2                           P70616
rc_AA893158_at annexin A7 63.4 48.8 -1.1                           P40615
AA850219_at Annexin III (Lipocortin III) 81.6 59 -1.3                           P14669
U90829_at APP-binding protein 1 469.3 359 -1.2
AF026505_at Arg/Abl-interacting protein ArgBP2 57.4 77 -1.2                           O35413
rc_AA891194_s_at Arg/Abl-interacting protein ArgBP2 176.9 141.4 -1.3                           P03996
U07201_at Asparagine synthetase 90.1 76.9 -1.3                           Q07258
D13120_s_at ATP synthase subunit d 1720.4 1909.2 1.1                           Q01713
rc_AA799778_at ATP synthase, H+ transporting, mitochondrial 99.6 1523.8 13.0                           Q9Z2J3
 F0 complex, subunit b, isoform 1
rc_AI230614_s_at ATPase Na+/K+ transporting beta 1 polypeptide 20 105.3 6.1
M99223_at ATPase, Ca++ transporting, cardiac muscle, 61.5 119.6 1.5                           P31232
fast twitch 1
AA799276_at ATPase, Ca++ transporting, cardiac muscle, 1443.5 1708.1 1.1          
slow twitch 2
U29339_at avian erythroblastosis oncogene B 3 107.4 131.3 1.3
AF009329_at basic helix-loop-helix domain containing, class B3 196.7 212.9 1.1                           O35779
rc_AA859830_s_at biglycan 207 475 2.3
D49955_at bone marrow stromal cell antigen 1 4.8 19.3 3.7                           Q63714
S75359_s_at bone morphogenetic protein receptor, type 1A 90.2 207.2 1.7
D14441_at brain acidic membrane protein 438.6 298.8 -1.2
rc_AI030286_s_at brain derived neurotrophic factor 23 14.2 -1.4                           O70437
U68417_at branched chain aminotransferase 2, mitochondrial 189.6 133 -1.3                           P54844
rc_AI102839_g_at calbindin 1 57.8 116 2.0
M86621_at calcium channel,voltage-dependent, alpha2/delta s.u.1 189.1 246.7 1.3                           P26769
L13407_i_at calcium/calmodulin-dependent protein kinase II, delta 17.5 13.8 -1.3                           P15650
rc_AI180288_s_at Caldesmon 1 151.1 145.3 -1.2                           O08876
X53363cds_s_at calreticulin 834.5 959.7 1.1
AF037072_at carbonic anhydrase 3 171.8 112.9 -1.6                           P14141
rc_AA800851_s_at carboxylesterase 3 44.8 36.1 -1.3                           P19357
L07736_at carnitine palmitoyltransferase 1 39.9 198 4.6                           P09057
U22297_at casein kinase 1 gamma 2 isoform 244 196.1 -1.2                           P22829
M11670_at Catalase 71.6 84.7 1.1                           Q923V7
rc_AA926149_g_at Catalase 127.5 138 1.2
rc_AI235585_s_at cathepsin D 663.7 956.9 1.2
rc_AI043968_at caveolin 3 1030 800 -1.2                           P47198
rc_AI043968_g_at caveolin 3 1448.1 1018.1 -1.3                           Q63617
rc_AA946292_at CCAAT/enhancerbinding, protein (C/EBP) delta 40.8 58.5 1.7                           P04762
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Probe_set name Sig. ConSig.Lin F.Ch Swisprot
rc_AI103957_g_at CD 81 antigen 86.6 62.8 -1.3                           P48317
D82928_at CDP-diacylglycerol--inositol 3-phosphatidyltransferase (phosphatidylinositol synthase) 458.4 396.2 -1.1                           Q63788
(phosphatidylinositol synthase)
rc_AA925473_g_at cell division cycle 42 homolog (S. cerevisiae) 1134.4 941.9 -1.2                           P16036
Y12178_at Ceruloplasmin (ferroxidase) 4.3 9.4 1.6
AJ010828_at chemokine orphan receptor 1 108.6 127 1.2                           O89039
X74402_at choline transporter 177.2 131.2 -1.1                           Q8K1F5
X74834cds_s_at cholinergic receptor, nicotinic, alpha polypeptide 1 968.8 1282.9 1.3                           Q63258
X74836cds_s_at cholinergic receptor, nicotinic, delta polypeptide 43.8 104.1 1.5                           P28570
X77235_at cholinergic receptor, nicotinic, epsilon polypeptide 118.6 78.8 -1.3                           P50398
X74835cds_at cholinergic receptor, nicotinic, gamma polypeptide 558.1 706.3 1.3                           Q63258
rc_AA892559_at Ciliary neurotropic factor 7.5 21.2 2.0                           O08622
rc_AA859757_at collagen, type V, alpha 1 187.3 147.4 -1.2
AJ005394_at collagen, type V, alpha 1 471.8 426.8 -1.1                           O70603
rc_AA859757_g_at collagen, type V, alpha 1 924.1 695.7 -1.2                           P50878
rc_AA894304_at Complement component 3 694.4 521.9 -1.3                           P40615
M10140_at creatine kinase, muscle 1045.9 1408.4 1.3                           P41135
X75207_s_at cyclin D1 194.6 218.1 1.1
rc_AI234146_at cysteine rich protein 1 737.6 601.8 -1.2                           P27817
rc_AA800784_at cysteine rich protein 61 230.7 147.2 -2.0                           O08589
Y12517cds_at cytochrome b5,outer mitochondrial membrane isoform 96.2 99 -1.2                           Q64346
rc_AA997614_s_at cytochrome P450, subfamily 51 386.5 166.5 -2.3                           P35281
AB004096_at cytochrome P450, subfamily 51 405.5 193.3 -1.9                           Q64654
rc_AA963449_s_at cytochrome P450, subfamily 51 753.9 332.4 -2.0                           Q62833
U17697_s_at cytochrome P450, subfamily 51 805.4 497.5 -1.7                           Q64536
AF038591_at cytoplasmic aminopeptidase P 301.7 262.2 -1.1                           O54975
X60328_g_at cytosolic epoxide hydrolase 52.8 64.8 1.3
Z36980_at D-dopachrome tautomerase 260.7 212.6 -1.2                           P04166
AF055884_s_at DEAF-1 related transcriptional regulator (NUDR) 76.3 99.6 1.3                           O88450
rc_AA963839_s_at diaphorase 1 616.3 469.2 -1.2                           Q03484
rc_AI229440_s_at diaphorase 1 977.6 825.2 -1.1                           Q01986
D00636Poly_A_Site#1_s_atdiaphorase 1 1889.8 1542.2 -1.2                           Q9Z1K4
U49049_at discs, large (Drosophila) homolog 2 (chapsyn-110) 19 16 -1.3                           Q62809
U50717_s_at discs, large (Drosophila) homolog 2 (chapsyn-110) 75 74.9 -1.2                           Q64303
U67994_at DNA primase, p49 subunit 4.4 166.9 48.5                           P54102
rc_AI011998_at dnaJ homolog, subfamily b, member 9 18.7 271.1 7.0                           P53812
U53922_at DnaJ-like protein 706.7 829.6 1.1                           Q62920
X94185cds_s_at dual specificity phosphatase 6 94.5 122.6 1.3                           P18916
U42627_at dual specificity phosphatase 6 159.2 209.6 1.3                           Q62784
X54531mRNA_at dynamin 1 137.8 174.9 1.2
AF020210_s_at dynamin 1-like 58.5 55.4 -1.2                           O35303 
rc_AA892562_g_at dyskeratosis congenita 1, dyskerin 68.7 200.3 2.0                           Q63413
rc_AA892562_at dyskeratosis congenita 1, dyskerin 173.6 285.1 1.7                           P00507
M18416_at early growth response 1 58.6 75.9 1.4                           P12369
AF023087_s_at early growth response 1 287.1 416 1.4                           P08154
U36482_g_at endoplasmic retuclum protein 29 574.6 696.4 1.1
U48247_g_at enigma homolog 119.9 84.3 -1.3                           P97659
rc_AA851223_at enolase 3, beta 307.7 1339.9 2.5                           P12346
U08976_at enoyl coenzyme A hydratase 1 260.6 378.5 1.5                           Q07258
rc_AA684631_at ESTs, Weakly similar to  ankycorbin; NORPEG-like protein [Mus musculus] [M.musculus] 143.2 173.9 1.1
U05014_at eukaryotic translation initiation factor 4E binding protein 1 479.2 400 -1.1                           Q64308
rc_AI180442_at farensyl diphosphate synthase 470.5 207.6 -2.3                           P29411
U72497_at fatty acid amide hydrolase 72.2 93.1 1.2                           P97577
rc_AA893242_g_at fatty acid Coenzyme A ligase, long chain 2 101.3 72.1 -1.3
rc_AI236284_s_at fatty acid Coenzyme A ligase, long chain 4 209.1 136.5 -1.3
X56551cds_at fibroblast growth factor 7 28.3 82.1 2.5                                 
M28259cds_at Fibronectin 1 151.8 112.4 -1.2       
rc_AA891769_at Fibronectin 1 424 482.7 1.1                           O88548
rc_AA799645_g_at FXYD domain-containing ion transport regulator 1 32.7 78.6 1.7                           P16632
rc_AA799645_at FXYD domain-containing ion transport regulator 1 167.3 187.5 1.2                           P54290
rc_AA946251_at G protein-coupled receptor kinase 5 14.3 27.9 1.4                           P30009
X74800_at GDP-dissociation inhibitor 1 319.3 203 -1.4                           Q8K1F5
rc_AA800912_at general transcription factor II I repeat domain-containing 1 96.7 81.8 -1.2                           P19511
X07467_at glucose-6-phosphate dehydrogenase 365.2 290.4 -1.2                           Q9Z1A5
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rc_AA892012_g_at Glutamate oxaloacetate transaminase 2, mitochondrial (aspartate aminotransferase 2)258.4 202.4 -1.3
AF090113_g_at glutamate receptor interacting protein 2 111.4 77.3 -1.3                           O88961
J03914cds_s_at Glutathione-S-transferase, mu type 2 (Yb2) 390.4 317.8 -1.2                           P09495
U96130_at glycogenin 309.1 365.6 1.2
rc_AA859804_at GM2 ganglioside activator protein 335.6 280.7 -1.2                           Q62639
D25543_at golgi-associated protein GCP360 111.9 99.1 -1.2                           Q63429
D25543_g_at golgi-associated protein GCP360 222.6 160.1 -1.3
rc_AI070295_g_at growth arrest and DNA-damage-inducible 45 alpha 279.4 319.1 1.1                                   
rc_AI070295_at growth arrest and DNA-damage-inducible 45 alpha 261.6 350.6 1.2                                  
U77829mRNA_s_at growth arrest specific 5 151 119.5 -1.2                           P30823
U77829mRNA_i_at growth arrest specific 5 403.3 303.8 -1.4                           P70605
L13619_at growth response protein (CL-6) 314.5 133.8 -2.5                             
L13619_g_at growth response protein (CL-6) 340.4 184.3 -2.1                           P32198
AF077354_at heat shock 70 kDa protein 4 48.5 65.4 1.4                           O88600
M14050_s_at heat shock 70kD protein 5 941.3 775.5 -1.2                           P00388
U05013_at heme oxygenase 2 114.7 156.4 1.1
X62875mRNA_g_at high mobility group AT-hook 1 117.8 258.9 2.5
X62875mRNA_at high mobility group AT-hook 1 224.6 642.2 2.1
rc_AA944177_at high mobility group box 1 18.7 23.4 1.2                           P30009
rc_AI029805_at high mobility group box 1 17.5 79.3 3.2                           P70490
rc_AI232374_at Histone H1-0 437.4 818.9 2.0                           P20070
rc_AI232374_g_at Histone H1-0 190.1 843.5 2.8                           P41137
rc_AA892014_s_at HLA-B-associated transcript 1A 515.8 422.8 -1.2                           P16975
rc_AA799735_at homer, neuronal immediate early gene, 1 319.4 271 -1.1                           Q63139
M65251_s_at human immunodeficiency virus type 1 enhancer 38.1 142.7 3.7                           P20607
-binding protein 2
D37951UTR#1_at human immunodeficiency virus type 1 enhancer- 131.9 151.7 1.1                           Q63714
binding protein 2
rc_AI105448_at hydroxysteroid 11-beta dehydrogenase 1 323.4 555.8 1.6                           O08876
rc_AI236145_at hydroxysteroid dehydrogenase 17 beta, type 7 27.9 21.5 -1.3                           O55081
U21718mRNA_at hypothetical RNA binding protein RDA288 647.4 557.8 -1.1                           O35804
Y09507_at hypoxia inducible factor 1, alpha subunit 84.6 67.1 -1.3
U17254_at immediate early gene transcription factor NGFI-B 32.5 48.6 1.5                           Q62655
U17254_g_at immediate early gene transcription factor NGFI-B 22.4 79.2 3.5                           Q64536
rc_AI011179_at immunoglobulin binding protein 1 82.9 87.7 1.4
rc_AI230256_at Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein 54.7 67.5 1.2                           Q62736
rc_AI171268_at Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein 24.4 98.1 2.8                           Q62745
U26397_at inositol polyphosphate-4-phosphatase, type 1 90.2 106.6 1.1                           P22829
X58375_at Insulin receptor substrate 1 36.9 24.7 -1.4                           P14423
M17960_at Insulin-like growth factor II (somatomedin A) 26 13.9 -1.6                           P12369
X66494_at integrin alpha 7 110.7 158.4 1.3                           P80299
X65036_at integrin alpha 7 1782.4 1487.5 -1.1                           P35570
M26744_at Interleukin 6 (interferon, beta 2) 39.5 33.8 -1.3                           P06536
rc_AA892314_at isocitrate dehydrogenase 1 193.8 138.2 -1.3                           P04937
rc_AI102838_s_at Isovaleryl Coenzyme A dehydrogenase 144 115 -1.2
AJ000557cds_s_at Janus kinase 2 (a protein tyrosine kinase) 78.2 49 -1.2                           O35804
U13396_at Janus kinase 2 (a protein tyrosine kinase) 111.2 59.8 -1.5                           P49088
U13396_g_at Janus kinase 2 (a protein tyrosine kinase) 120.2 95.8 -1.3                           Q62651
U58858_at junction plakoglobin 182.1 134.9 -1.2                           Q62947
AF083330_at kinesin family member 3C 87.4 66.1 -1.3                           O55165
L26292_at Kruppel-like factor 4 (gut) 285.7 227.7 -1.3
D12769_at Kruppel-like factor 9 45.9 62.4 1.3                           P08461
D12769_g_at Kruppel-like factor 9 204.7 272 1.3                           P28677
U07181_at lactate dehydrogenase B 111.8 146.3 1.3                           P37140
U07181_g_at lactate dehydrogenase B 93.6 188.7 1.9                           Q62609
rc_AI232078_at LanC (bacterial lantibiotic synthetase component C)-like 1 717.1 818.8 1.1                           O70436
rc_AA859783_at large subunit ribosomal protein L36a 720.8 1590 1.7                           P15429
J02962_at lectin, galactose binding, soluble 3 111.9 93.8 -1.1                           O88548
X13722 Low density lipoprotein receptor -2.8 88 239 P35952
rc_AA892810_at low density lipoprotein receptor-related protein associated protein 1 67.8 78.9 1.1                           P20294
rc_AI237535_s_at LPS-induced TNF-alpha factor 283 238.3 -1.2                           Q00918
X84039_at lumican 968.2 1081.7 1.1
rc_AI234060_s_at lysyl oxidase 308.1 219.1 -1.3
AF067727_s_at MAD homolog 1 (Drosophila) 39.6 24.9 -1.4                           P97588
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rc_AI228675_at MAD homolog 2 (Drosophila) 37.8 26.4 -1.5                           O70185
AB017912_at MAD homolog 2 (Drosophila) 245.3 184.4 -1.1                           O70436
rc_AI008639_at MAD homolog 4 (Drosophila) 22.1 91.3 3.2                           P20070
U09870_at major vault protein 191 238.1 1.4
rc_AI010480_g_at malate dehydrogenase mitochondrial 1843.9 2039 1.1
rc_AI171506_g_at Malic enzyme 1, soluble 462.5 383.3 -1.1
M63485_at matrin 3 84.9 171.6 2.1                           P14882
X83537_at matrix metalloproteinase 14, membrane-inserted 359.8 474 1.2
rc_AA891916_g_at membrane interacting protein of RGS16 449.5 370.8 -1.1                           Q63399
rc_AI102562_at Metallothionein 74 103.7 1.4
rc_AA924198_s_at mevalonate kinase 117.9 76.7 -1.5
U53706_at mevalonate pyrophosphate decarboxylase 121.7 97.1 -1.3                           Q64346
rc_AI008638_at milk fat globule-EGF factor 8 protein 524.2 1038 1.4                           Q64654
rc_AI639082_s_at mini chromosome maintenance deficient 6 (S. cerevisiae) 52.7 412.2 6.1                           P43278
U73142_g_at mitogen activated protein kinase 14 188.7 244.3 1.2                           O35854
rc_AI171630_s_at mitogen activated protein kinase 14 190.6 278.5 1.3                           P16232
rc_AI178835_at mitogen activated protein kinase kinase 1 25.7 11.3 -1.9                           O35532
AF004811_at moesin 156 139.1 -1.2                           O35763
rc_AI105076_s_at Murine thymoma viral (v-akt) oncogene homolog 2 120.5 86.6 -1.3                           P48317
M27151_at myogenic factor 6 13.2 24.9 1.6
L00370cds_s_at myosin, heavy polypeptide 3 715.4 444.1 -1.5                           P08010
rc_AA859896_at myristoylated alanine rich protein kinase C substrate 2.3 23.7 5.7                           Q62809
rc_AA925762_at myristoylated alanine rich protein kinase C substrate 70.7 63.5 -1.2                           Q99068
rc_AA955167_s_at myristoylated alanine rich protein kinase C substrate 107.9 93.7 -1.2
rc_AA899253_at myristoylated alanine rich protein kinase C substrate 393 319.9 -1.2
J02679_s_at NAD(P)H dehydrogenase, quinone 1 1536.9 1980 1.3
rc_AI137246_s_at neural cell adhesion molecule 1 490.3 399.5 -1.2                           Q64320
U88958_at neuritin 122.2 152.2 1.3
AJ007288_at neutrophil collagenease 25.5 1.6 -14.9                           O88766
rc_AA799423_at nexilin 1001.7 800.8 -1.2                           P13721
rc_AA859752_at Noggin 31.5 21.9 -1.4                   
U31203_at Noggin 109.9 95.1 -1.2                           Q62744
AF036335_at NonO/p54nrb homolog 47.3 217.7 3.7                           O54725
AF036335_g_at NonO/p54nrb homolog 5.8 302.4 45.3                           O54725
AF077338_at norvegicus myosin binding protein H 1816.6 1579.1 -1.1                           O88599
rc_AI176488_at nuclear factor I/B 55.8 64.9 1.1                           P70618
AF014503_at nuclear protein 1 1179.6 1003.5 -1.1                           O54842
M14053_at nuclear receptor subfamily 3, group C, member 1 26.7 36.1 1.3                           P00564
rc_AI230572_at nuclease sensitive element binding protein 1 33.7 95.5 1.9                           O55081
rc_AA944007_at nucleobindin 219.7 598.7 1.9
rc_AA891045_at nucleoporin p58 12.1 15.9 1.2                           P28480
U03416_at olfactomedin related ER localized protein 352.4 283.4 -1.2
J04792_at ornithine decarboxylase 1 396.4 441.6 1.1                           P08699
U41853_at oxygen regulated protein (150kD) 60.8 43.5 -1.3                           Q62762
rc_AI009098_at oxygen regulated protein (150kD) 327.7 255.5 -1.1                           Q64654
U35345_s_at p21 (CDKN1A)-activated kinase 2 56.3 40.7 -1.3                           Q8VHU3
X98490cds_at p32-subunit of replication protein A 90.8 103.1 1.2                           P09660
M10068mRNA_s_at P450 (cytochrome) oxidoreductase 180.2 138.8 -1.2
AF067790_s_at palmitoyl-protein thioesterase 2 22.2 84.4 3.7                           O70489
rc_H33491_at phenylalkylamine Ca2+ antagonist (emopamil) binding protein 127.2 69.3 -1.6                           P47875
AF080568_at phosphate cytidylyltransferase 2, ethanolamine 435.9 307.9 -1.3                           O88637
AF080568_g_at phosphate cytidylyltransferase 2, ethanolamine 416.8 313.4 -1.2                           O88637
D64046_at phosphatidylinositol 3-kinase, regulatory subunit, 48.6 56.1 1.2                           Q00900
polypeptide 2
D64046_g_at phosphatidylinositol 3-kinase, regulatory subunit, 19.8 76.6 3.7                           Q63072
polypeptide 2
D88666_at phosphatidylserine-specific phospholipase A1 302.3 432.9 1.4                           P70500
X51529_at phospholipase A2, group IIA (platelets, synovial fluid) 28.6 46.9 1.4
rc_AA998446_s_at phosphotidylinositol transfer protein, beta 242 177.9 -1.2                           Q15815
X64563cds_at plasminogen activator inhibitor 2 type A 36.9 29.2 -1.4                           Q02195
U72620_at pleiomorphic adenoma gene-like 1 425.9 348 -1.2                           P97599
AB020504_at PMF32 protein 145.2 109.2 -1.3                           Q9Z2X7
AB020504_g_at PMF32 protein 239.7 166.2 -1.4                           Q9Z2X7
U69884_at potassium intermediate/small conductance 18.6 28.9 1.5                           Q62981
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X17053mRNA_s_at small inducible cytokine A2 261.9 432 1.5
rc_AA799760_s_at solute carrier family 2 , member 4 10 39.6 3.2                                
S68135_s_at solute carrier family 2,member 1 75.1 32.7 -2.1
D12770_s_at solute carrier family 25 (mitochondrial adenine 1845.3 2183.3 1.2                           Q01713
nucleotide translocator) member 4
rc_AA892776_at solute carrier family 25 (mitochondrial carrier; adenine 939.7 2066.7 1.5                           Q99MI5
nucleotide translocator), member 3
U70476_at solute carrier family 7, member 1 154.1 120.1 -1.2                           P70565
rc_AA892557_at spermidine synthase 148.6 185.8 1.1                           Q9JL55
rc_AA955859_at splicing factor, arginine/serine-rich 28.2 41.2 1.3
 (transformer 2 Drosophila homolog) 10
AJ004858_at SRY-box containing gene 11 50.2 38.7 -1.2                           Q04889
M81639_at stannin 103.6 493.9 3.2                           P18297
rc_AI175764_s_at stearoyl-Coenzyme A desaturase 1 25.6 6.2 -4.6
rc_AA875269_at stearoyl-Coenzyme A desaturase 2 2173.3 1132.7 -1.9
rc_AI172293_at sterol-C4-methyl oxidase-like 1312.5 896.5 -1.4                           P13596
U39546_at surface protein MCA-32 12 29.9 2.3
D78359_at sushi-repeat-containing protein 236 191.3 -1.2                           Q03527
S45663_g_at synaptic glycoprotein SC2 1300.3 995.7 -1.2
S45663_at synaptic glycoprotein SC2 1679.6 1307.9 -1.2                           Q62904
U90312_at Synaptojanin II 86.4 104.3 1.2                           P70618
X75785_at Synaptonemal complex protein 3 2.8 4 2.1
rc_AA892759_at synaptosomal-associated protein, 23 kD 237.6 204 -1.1                           P41562
rc_AI102079_at Syntaxin binding protein 1 384.3 538.5 1.4                           P51638
rc_AA859980_at T-complex 1 734 350.5 -2.0                           O70603
rc_AA859980_g_at T-complex 1 1313.2 541.8 -2.1                           P09896
rc_AI071299_at TGFB inducible early growth response 21.6 33 1.3                           P51638
rc_AI172476_at TGFB inducible early growth response 79 133 1.5                           P30120
rc_AI169327_g_at tissue inhibitor of metalloproteinase 1 518.8 442 -1.1                        
rc_AA799340_at tissue inhibitor of metalloproteinase 2 1592.6 1863.3 1.1                           P13721
rc_AA899854_at topoisomerase (DNA) 2 alpha 427 502.1 1.2
rc_AA926242_at trans-golgi network protein 1 11.6 16.5 1.5
U09228_at transcription factor 4 105.2 76.5 -1.3                           Q62622
U51583_at transcription factor 8 82.6 173.1 1.4                           Q63617
rc_AA800787_at Transferrin 702.8 559.8 -1.2                               
U03491_g_at transforming growth factor, beta 3 194.8 284.4 1.4                           P11167
U03491_at transforming growth factor, beta 3 257.8 409 1.4                           P35355
M83107_at Transgelin (Smooth muscle 22 protein) 2340 1937 -1.1                           P43244
Z14030_at TRAP-complex gamma subunit 46.7 199.7 3.5                           O35800
X68101_at trg 114.8 136.6 1.1
rc_AA891880_at tricarboxylate carrier-like protein 221.8 172.6 -1.2
rc_AA891880_g_at tricarboxylate carrier-like protein 218.7 174.9 -1.2
J02780_at Tropomycin 4 441.4 365.2 -1.1                           P97535
Y15054_at tumor specific antigen 70 kDa 49.8 60.1 1.1                           O08651
S55223_s_at tyrosine 3-monooxgenase/tryptophan 5 monooxgenase 552.6 480.8 -1.1                           Q62724
activation protein, beta polypeptide
rc_AI236721_r_at tyrosine 3-monooxgenase/tryptophan 5-monooxgenase 103.8 79.7 -1.3
activation protein, gamma polypeptide
rc_AI180424_at Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 766.9 1563.3 2.1
activation protein, zeta polypeptide
U75397UTR#1_s_at U75397UTR#1 RNKROX2 Rattus norvegicus Krox-24 114.3 159.2 1.4
U75404UTR#1_s_at U75404UTR#1 RNU75404 Rattus norvegicus Ssecks 322 90 104.9 1.1
U75927UTR#1_at cytochrome oxidase subunit VIIa mRNA, 3' 61.8 89.7 1.4
 untranslated region, partial sequence
U95001UTR#1_s_at developmentally-regulated cardiac factor (DRCF-5) 207.2 537.3 1.9
D17296_at ubiquitin C 1965.8 3290.3 1.3                           P31399
U54632_g_at Ubiquitin conjugating enzyme E2I 422.6 616.9 1.3
AF047707_at UDP-glucose:ceramide glycosyltransferase 233.5 315.3 1.4                           Q9R0E0
rc_AI145931_at UDP-N-acetylglucosamine-2-epimerase/ 56.3 92.2 1.3
N-acetylmannosamine kinase
rc_AI008423_at unc-50 related protein (UNCL) 180.1 248.2 1.3
X74832cds_at unconventional myosin Myr2 I heavy chain 84.3 114.8 1.4                           P29524
AB010743_at Uncoupling protein 2, mitochondrial 92.2 261.2 3.0                           P56500
U40628_at unknown Glu-Pro dipeptide repeat protein 376.2 430.1 1.1
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rc_AA850885_s_at unknown Glu-Pro dipeptide repeat protein 2265.8 3650.5 1.6
rc_AA944014_at v-jun sarcoma virus 17 oncogene homolog (avian) 39 53.2 1.3                           P01026
rc_AA945867_at v-jun sarcoma virus 17 oncogene homolog (avian) 201.7 244.4 1.2                                
rc_AI175959_at v-jun sarcoma virus 17 oncogene homolog (avian) 792.2 913.9 1.1                           P41138
U56242_at v-maf musculoaponeurotic fibrosarcoma (avian) oncogene homolog (c-maf) 86 68 -1.2                           Q63622
Y00396mRNA_g_at v-myc avian myelocytomatosis viral oncogene homolog 132.1 110.9 -1.1    
X63722cds_s_at Vascular cell adhesion molecule 1 75.7 122.9 1.9
rc_AA850734_at vascular endothelial growth factor 101.6 97.2 -1.2                 
AF054826_at vesicle-associated membrane protein 5 424.4 293.6 -1.4                           Q9Z2J5
D10666_at visinin-like 1 203.6 144.1 -1.3
AF037272_at wap four-disulfide core domain 1 47.5 36.1 -1.4                           O70280
X07686cds_s_at X07686cds RNLB6 Rat L1Rn B6 repetitive DNA element 13.6 68.3 2.6
X07729exon#5_s_at X07729exon#5 RNEN4 R.norvegicus gene encoding neuron-specific enolase, exons 8-1262.6 155.3 2.5
X13527cds_s_at X13527cds RNFASACP Rat mRNA fragment for the acyl carrier protein domain of fatty acid synthetase505.2 397.4 -1.2
X14848cds#12_at X14848cds#12 MIRNXX Rattus norvegicus mitochondrial genome 15.6 18.2 1.2
X51536cds_g_at X51536cds RRRPS3 Rat mRNA for ribosomal protein S3 3154.2 3906.2 1.1
X54249mRNA_s_at X54249mRNA RRATBP1 Rat mRNA for a zinc finger protein AT-BP1, partial cds36.8 50 1.2
X56729mRNA_at X56729mRNA RSCALPST Rat mRNA for calpastatin 33.1 83.9 1.9
X60351cds_s_at X60351cds RRLENSABC R.rattus mRNA for alpha B-crystallin (ocular lens tissue)1040.6 1509.5 1.4
X62951mRNA_s_at X62951mRNA RNPBUS19 R.norvegicus mRNA (pBUS19) with repetitive elements90.3 111.2 1.3
X76489cds_g_at X76489cds RNCD9 R.norvegicus (Sprague Dawley) CD9 mRNA for cell surface glycoprotein289.2 427.7 1.2
X76489cds_at X76489cds RNCD9 R.norvegicus (Sprague Dawley) CD9 mRNA for cell surface glycoprotein139.3 440.9 2.8
X89697cds_at X89697cds RNTPCR07P R.norvegicus mRNA for TPCR07 protein 16.6 27.7 1.5
X89698cds_at X89698cds RNTPCR09P R.norvegicus mRNA for TPCR09 protein 19.6 29.3 1.7
X89699cds_at X89699cds RNTPCR10P R.norvegicus mRNA for TPCR10 protein 11.6 22.9 2.1
X97374exon_g_at X97374exon RNPPNEX2 R.norvegicus gene encoding prepronociceptin, exon 2106.7 128.2 1.1
rc_AI171167_at ZAP 36/annexin IV 76.9 270.1 3.2
U27186_at zinc finger protein 111 64.9 72.8 1.2                           Q64654
U56862_at zinc finger protein 260 69.5 51.2 -1.2                           Q63622
L16995_at ADD1/sterol regulatory element binding factor 1 170.3 73 -2.5
AJ005023_at MHC class Ia A1b antigen 144.6 102.8 -1.2
D17521_at protein kinase C-regulated chloride channel(ClC-3) 119 151.9 1.2                           Q63555
S63521_i_at glucose-regulated protein GRP78 388.4 299.8 -1.3                           P41123
D87991_at UDP-galactose transporter related isozyme 1 420 327.3 -1.2                           Q63788
Z12158cds_at pyruvate dehydrogenase E1 alpha form 1 subunit 546.6 424.9 -1.1
X80130cds_i_at alpha-actin cardiac protein 674.1 487.9 -1.4                           P25108
D87991_g_at  UDP-galactose transporter related isozyme 1 748.4 636.4 -1.2                           Q63769
U77931_at rRNA promoter binding protein 1091.5 894.4 -1.2                           P97612
X12367cds_s_at glutathione peroxidase I 1626.2 1439.1 -1.1                           O35823
X15013cds_at ribosomal protein L7a 1783.2 1647.6 1.1
X06801cds_i_at vaskular alpha-actin 2869.4 2410.9 -1.2                           P70473
X15013cds_g_at ribosomal protein L7a 2210.9 2461.6 1.1                           P05713
X51707cds_s_at ribosomal protein S19 2163.2 2568.6 1.1                                
X51706cds_at ribosomal protein L9 2617.1 2967.5 1.1
X51706cds_g_at ribosomal protein L9 2573.6 2998.2 1.1                           P20280
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rc_AA799330_at ESTs 176.9 218.5 1.1
rc_AA799396_g_at ESTs 449.7 361.8 -1.2
rc_AA799406_at ESTs 531.4 451.5 -1.1
rc_AA799467_at ESTs 70.2 112 1.3
rc_AA799539_at ESTs 85.4 68 -1.3
rc_AA799591_at ESTs 188.4 196.4 1.1
rc_AA799601_at ESTs 135.6 105.9 -1.2
rc_AA799616_at ESTs 310.8 247.3 -1.1
rc_AA799637_at ESTs 33.4 17.4 -1.2
rc_AA799637_g_at ESTs 42.6 22.5 -1.3
rc_AA799680_at ESTs 254.8 217.6 -1.1
rc_AA799691_at ESTs 253.4 208.4 -1.2
rc_AA799721_g_at ESTs 200.3 174.1 -1.2
rc_AA799751_at ESTs 284.2 329.6 1.1
rc_AA799773_at ESTs 1206.7 876.8 -1.3
rc_AA799773_g_at ESTs 1456.6 1105.3 -1.3
rc_AA799832_at ESTs 587.7 700.1 1.2
rc_AA799899_i_at ESTs 3701.2 3163.1 -1.1
rc_AA800017_at ESTs 102.3 122.2 1.1
rc_AA800034_at ESTs 917.5 867.1 -1.1
rc_AA800036_at ESTs 278.1 270.9 -1.2
rc_AA800039_s_at ESTs 498.5 430 -1.1
rc_AA800176_at ESTs 64.6 52.8 -1.2
rc_AA800199_at ESTs 130.8 101.6 -1.2
rc_AA800200_at ESTs 41.5 31.3 -1.3
rc_AA800202_at ESTs 8.5 8.5 1.4
rc_AA800206_at ESTs 76.3 60 -1.4
rc_AA800218_at ESTs 250.9 231.3 -1.1
rc_AA800315_at ESTs 69.2 62.2 -1.1
rc_AA800576_at ESTs 606.7 417.9 -1.3
rc_AA800622_at ESTs 313 273.6 -1.1
rc_AA800678_g_at ESTs 812.6 687.8 -1.2
rc_AA800686_at ESTs 73.9 34.2 -1.7
rc_AA800693_g_at ESTs 137.2 114.6 -1.2
rc_AA800711_at ESTs 66.8 45 -1.4
rc_AA800737_at ESTs 140 109.5 -1.3
rc_AA800750_f_at ESTs 110.2 139.1 1.1
rc_AA800772_at ESTs 32.9 37.3 -1.3
rc_AA800850_at ESTs 426.7 359.6 -1.2
rc_AA800881_at ESTs 59.3 34.1 -1.6
rc_AA858588_g_at ESTs 344.3 296.4 -1.1
rc_AA858617_at ESTs 75.3 106.5 1.1
rc_AA859520_at ESTs 87 135.4 1.5
rc_AA859536_at ESTs 1147.4 881.9 -1.3
rc_AA859562_at ESTs 118.3 129.3 1.2
rc_AA859585_at ESTs 343.3 416.2 1.2
rc_AA859627_at ESTs 11.4 15.7 1.4
rc_AA859633_at ESTs 26.7 22.9 -1.3
rc_AA859633_g_at ESTs 132.1 78.4 -1.3
rc_AA859690_at ESTs 59.2 79.6 1.2
rc_AA859725_at ESTs 24.3 40.3 1.5
rc_AA866234_at ESTs 501.4 597.9 1.1
rc_AA866276_at ESTs 1266.7 1021.4 -1.2
rc_AA866299_at ESTs 219 219.9 -1.2
rc_AA866299_g_at ESTs 224.7 181.9 -1.1
rc_AA866454_at ESTs 378.2 277.4 -1.2
rc_AA874827_at ESTs 91.1 123.9 1.2
rc_AA874912_at ESTs 17.3 29.5 1.7
rc_AA874928_g_at ESTs 317.2 358.3 1.1
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rc_AA874943_at ESTs 381 318.2 -1.3
rc_AA875098_at ESTs 139.7 110 -1.2
rc_AA875126_at ESTs 49.7 37 -1.2
rc_AA875215_at ESTs 23.5 37.2 1.4
rc_AA875255_at ESTs 33.9 21.6 -1.6
rc_AA875263_at ESTs 368 298.7 -1.2
rc_AA875288_at ESTs 46.2 32.3 -1.4
rc_AA875327_at ESTs 449.5 366.7 -1.1
rc_AA875444_at ESTs 20.1 13.4 -1.5
rc_AA875495_at ESTs 152.2 114.5 -1.3
rc_AA875523_r_at ESTs 284.5 224.4 -1.3
rc_AA875615_at ESTs 15.5 11 -1.1
rc_AA875620_at ESTs 173.5 113.2 -1.4
rc_AA875620_g_at ESTs 301.6 215.4 -1.3
rc_AA875633_at ESTs 390.1 320.6 -1.1
rc_AA891308_at ESTs 136.7 92.5 -1.3
rc_AA891595_at ESTs 140.1 101.9 -1.3
rc_AA891631_at ESTs 11.4 19.1 1.3
rc_AA891669_g_at ESTs 501.8 684.9 1.3
rc_AA891724_at ESTs 440.4 274.9 -1.4
rc_AA891727_at ESTs 315.9 250.6 -1.2
rc_AA891940_at ESTs 588.8 595.5 1.1
rc_AA891944_at ESTs 50.6 72.8 1.3
rc_AA892006_g_at ESTs 268.3 217.9 -1.2
rc_AA892120_at ESTs 145.7 184.8 1.2
rc_AA892154_g_at ESTs 190.7 164.8 -1.1
rc_AA892238_at ESTs 330.4 291 -1.1
rc_AA892248_at ESTs 1555.4 1955.2 1.3
rc_AA892248_g_at ESTs 2074.7 2504.1 1.2
rc_AA892273_at ESTs 189.8 216.1 1.2
rc_AA892284_at ESTs 139.3 162.5 1.1
rc_AA892300_at ESTs 141.5 108.6 -1.2
rc_AA892310_at ESTs 113.8 94.6 -1.2
rc_AA892364_at ESTs 138.5 134 1.1
rc_AA892378_at ESTs 326.5 274.6 -1.1
rc_AA892378_g_at ESTs 802.2 656.5 -1.2
rc_AA892399_at ESTs 63.9 58.8 -1.2
rc_AA892768_at ESTs 282.1 235.1 -1.1
rc_AA892779_at ESTs 97.8 86.6 -1.2
rc_AA892789_at ESTs 196.9 243.7 1.1
rc_AA892832_at ESTs 877.2 723.6 -1.1
rc_AA892847_at ESTs 73.5 55.5 -1.3
rc_AA892851_g_at ESTs 277.4 216.1 -1.2
rc_AA893022_at ESTs 132.1 103.3 -1.2
rc_AA893032_at ESTs 75.3 39.1 -2.0
rc_AA893172_at ESTs 98.6 84.6 -1.1
rc_AA893183_g_at ESTs 53 72.4 1.4
rc_AA893185_at ESTs 528.4 619.4 1.1
rc_AA893230_at ESTs 14 18.1 1.3
rc_AA893273_at ESTs 85.1 44.5 -1.3
rc_AA893357_at ESTs 267.1 323.6 1.2
rc_AA893493_i_at ESTs 2656.9 2025.6 -1.2
rc_AA893641_at ESTs 91.5 71.7 -1.2
rc_AA893641_g_at ESTs 176.8 140 -1.2
rc_AA893659_at ESTs 195.1 158.4 -1.2
rc_AA893717_at ESTs 286.3 315.4 1.1
rc_AA893811_at ESTs 341 263.3 -1.2
rc_AA893994_at ESTs 13 11.8 -1.4
rc_AA894092_at ESTs 41.1 38.4 -1.2
rc_AA894200_at ESTs 175.7 139 -1.2
rc_AA894200_g_at ESTs 2180.3 1821.3 -1.2
rc_AA894264_at ESTs 55.9 28.9 -1.7
rc_AA894282_at ESTs 284.5 193.6 -1.1
rc_AA894312_at ESTs 166.5 138.8 -1.1
rc_AA894318_at ESTs 356.9 260.5 -1.4
rc_AA894345_at ESTs 464.7 373.2 -1.2
rc_AI007614_at ESTs 22.8 30.4 1.4
rc_AI007824_at ESTs 2553.8 2936.1 1.1
rc_AI010580_s_at ESTs 165.8 217.7 1.3
rc_AI102868_g_at ESTs 583.4 679.8 1.1
Appendix
85
Probe_set Name Sig. Con Sig.Lin F.Ch
rc_AI176422_g_at ESTs 117 189.5 1.3
rc_AI176456_at ESTs 57.2 88.9 1.1
rc_AI177404_at ESTs 104 240.4 2.0
rc_AI229924_at ESTs 70.9 85.9 1.2
rc_AI236601_at ESTs 359.3 465.7 1.2
rc_AI237007_at ESTs 33.2 44.9 1.5
rc_AI638939_at ESTs 54.3 70.4 1.2
rc_AI638949_s_at ESTs 225.7 195.5 -1.1
rc_AI638989_at ESTs 310.5 451.5 1.4
rc_AI639008_at ESTs 79.8 313.3 4.3
rc_AI639042_at ESTs 2.4 75.6 22.6
rc_AI639043_at ESTs 4.3 31.6 6.1
rc_AI639045_at ESTs 9.9 73.2 4.0
rc_AI639058_s_at ESTs 1073.2 1332.6 1.2
rc_AI639119_at ESTs 2.8 17.7 3.7
rc_AI639120_at ESTs 85.1 173.4 4.9
rc_AI639148_at ESTs 35.9 40.1 1.2
rc_AI639154_at ESTs 22.8 53.7 2.1
rc_AI639155_at ESTs 1.1 89.2 27.9
rc_AI639188_at ESTs 49.5 334.6 4.9
rc_AI639255_at ESTs 85.1 101.6 1.1
rc_AI639260_at ESTs 2.7 16.2 3.2
rc_AI639289_at ESTs 21.2 24.8 1.2
rc_AI639305_at ESTs 9.8 36.4 3.0
rc_AI639305_g_at ESTs 6.8 31.7 4.9
rc_AI639306_at ESTs 44.8 84.5 2.0
rc_AI639308_at ESTs 65.9 53.5 -1.3
rc_AI639336_at ESTs 13.5 65.4 4.6
rc_AI639339_at ESTs 0 18.8 194.0
rc_AI639371_at ESTs 5.8 13.4 2.3
rc_AI639372_at ESTs 22.6 96.3 2.6
rc_AI639381_at ESTs 81.7 116 1.2
rc_AI639410_i_at ESTs 0.8 48 48.5
rc_AI639410_s_at ESTs 32.3 293.1 8.6
rc_AI639411_at ESTs 7.7 183.3 27.9
rc_AI639411_g_at ESTs 185.4 561.5 2.8
rc_AI639412_at ESTs 5.6 45.6 4.0
rc_AI639447_at ESTs 104.6 143 1.5
rc_AI639474_at ESTs 39.4 223 6.1
rc_AI639475_at ESTs 1.3 53.1 18.4
rc_AI639476_s_at ESTs 240.4 271.6 1.2
rc_AI639510_at ESTs 10.4 39.2 2.6
rc_H31351_at ESTs 137.3 170 1.1
rc_H31479_at ESTs 225.1 195.3 -1.3
rc_H31588_at ESTs 38.9 70.6 1.6
rc_H31976_at ESTs 213.8 205 -1.2
rc_H33426_at ESTs 152.3 74.9 -1.9
rc_H33426_g_at ESTs 114.6 67.7 -1.7
